Vaccinia virus inducing cell fusion and its application

By defecting the K2L or HA gene of vaccinia virus, causing cell fusion, it solves the problem of insufficient proliferativeness in normal tissues, and achieves specific proliferation and destruction in cancer cells, significantly improving the anti-cancer effect.

CN113840914BActive Publication Date: 2024-11-05TOTTORI UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080035018.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-05-14
Filing Date
2020-05-12
Publication Date
2024-11-05
Estimated Expiration
2040-05-12

AI Technical Summary

Technical Problem

The existing vaccinia virus is weak in normal tissues and is difficult to grow specifically in cancer cells, affecting its application as a safe cancer virus therapy.

Method used

By defecting the K2L gene or HA gene of the vaccinia virus, the cells of infected cells are fusion, thereby improving their proliferation and destruction ability in cancer cells, and the vaccinia virus is modified through genetic recombination technology to make it specific in cancer cells Sexual proliferation and destruction.

Benefits of technology

Improve the anti-cancer effect of vaccinia virus, and by inducing cell fusion and immunogenic cell death, it enhances the infiltration and immune response of CD8 T cells, converts cold tumors into hot tumors, making them more vulnerable to immune attacks, and significantly improves the anti-cancer Effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0003347271570000011
    Figure HDA0003347271570000011
  • Figure HDA0003347271570000021
    Figure HDA0003347271570000021
  • Figure HDA0003347271570000022
    Figure HDA0003347271570000022
Patent Text Reader

Abstract

The object of the present invention is to provide a vaccinia virus that induces cell fusion of infected cells and a method for preparing the same. The present invention is a mutant vaccinia virus that can cause specific cell fusion of infected cells, wherein the functions of the K2L gene or the HA gene, or the K2L gene and the HA gene are defective, and the vaccinia virus causes cell fusion of infected cells and induces cell death.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a vaccinia virus that induces cell fusion of infected cells. Background Art

[0002] Currently, preclinical research and clinical trials of live virus therapy for cancer are being actively carried out around the world. This cancer virus therapy is a method of treating cancer by using the original properties of viruses, that is, killing infected cells and tissues while proliferating and spreading. Compared with conventional radiotherapy and chemotherapy, it exerts anti-cancer effects through multiple mechanisms, firstly, the use of oncolytic viruses for viral proliferation, and secondly, the induction of anti-tumor immunity that accompanies it.

[0003] Previously, there was a vaccine strain of vaccinia virus that was constructed in Japan and used as a smallpox vaccine for humans and has been proven to be highly safe (see Non-Patent Document 1). However, since it still maintains weak proliferation in normal tissues, it must be modified to grow only in cancer cells to make it a safer cancer virus therapy. Therefore, based on this vaccine strain, we will improve it through genetic recombination technology and use the abnormal regulation of the MAPK / ERK pathway in a wide range of cancers as an indicator to successfully develop a genetic recombinant vaccinia virus that specifically proliferates cancer cells and destroys cancer (see Patent Documents 1 and 2).

[0004] Prior art literature

[0005] Patent Literature

[0006] Patent Document 1: International Publication No. WO2011 / 125469

[0007] Patent Document 2: International Publication No. WO2015 / 076422

[0008] Non-patent literature

[0009] Non-patent document 1: Protein Nuclease, Vol.48No.12(2003), p.1693-1700 Summary of the invention

[0010] Problems to be solved by the invention

[0011] The object of the present invention is to provide a vaccinia virus that induces cell fusion of infected cells and a method for preparing the same.

[0012] Technical solutions to the problem

[0013] The present inventors, while studying the anti-tumor effect of vaccinia virus, found that if genes such as K2L gene or HA gene of vaccinia virus are defective, cell fusion of infected cells is induced, resulting in cell death. That is, anti-cancer effect is exhibited by infecting cancer cells with vaccinia virus with defective K2L gene or HA gene. Furthermore, the inventors found that synergistic anti-cancer effect is exerted by defective K2L gene or HA gene of oncolytic vaccinia virus, thereby completing the present invention.

[0014] That is, the present invention is as follows:

[0015] [1] A mutant vaccinia virus that is capable of causing cell fusion of infected cells.

[0016] [2] The vaccinia virus according to [1], wherein the function of the K2L gene or the HA gene, or the K2L gene and the HA gene is defective, and the vaccinia virus causes cell fusion of infected cells and induces cell death.

[0017] [3] The vaccinia virus according to [1] or [2], which is an oncolytic vaccinia virus.

[0018] [4] The vaccinia virus according to [3], which does not proliferate in normal cells but specifically proliferates in cancer cells and has oncolytic properties that specifically destroy cancer cells.

[0019] [5] The vaccinia virus according to any one of [1] to [4], wherein the vaccinia virus is LC16 strain, LC16mO strain, or LC16m8 strain modified to express the B5R gene.

[0020] [6] A pharmaceutical composition for treating cancer, comprising the vaccinia virus of any one of [1] to [5].

[0021] [7] A vaccinia virus vector, comprising the vaccinia virus according to any one of [1] to [5], into which foreign DNA has been introduced.

[0022] [8] The vaccinia virus vector according to [7], wherein the exogenous DNA is a marker DNA, a therapeutic gene having a cytotoxic or immunostimulatory effect, or a DNA encoding an antigen of a cancer, virus, bacterium or protozoa.

[0023] [9] A pharmaceutical composition for treating cancer or for use as a vaccine against cancer, virus, bacteria or protozoa, the pharmaceutical composition comprising the vaccinia virus vector of [7] or [8].

[0024]

[10] A method for preparing a vaccinia virus, wherein the vaccinia virus causes cell fusion of infected cells and induces cell death, the method comprising making the K2L gene or the HA gene, or the K2L gene and the HA gene of the vaccinia virus functionally defective.

[0025]

[11] According to the preparation method of

[10] , the vaccinia virus is an oncolytic vaccinia virus.

[0026]

[12] The preparation method according to

[10] or

[11] , wherein the preparation method further comprises making the function of the vaccinia virus growth factor (VGF) gene or the O1L gene, or the vaccinia virus growth factor (VGF) gene and the O1L gene defective.

[0027]

[13] The method according to any one of

[10] to

[12] , wherein the vaccinia virus is LC16 strain, LC16mO strain or LC16m8 strain modified to express the B5R gene.

[0028]

[14] A combination drug kit for treating cancer, comprising the vaccinia virus of any one of [1] to [5] in combination with an immune checkpoint inhibitor.

[0029]

[15] The combination drug kit according to

[14] , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.

[0030]

[16] The vaccinia virus according to any one of [1] to [5], which is used for treating cancer together with an immune checkpoint inhibitor.

[0031]

[17] The vaccinia virus according to

[16] , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.

[0032] This specification includes the disclosure of Japanese Patent Application No. 2019-91609 on which the priority of this application is based.

[0033] Effects of the Invention

[0034] If genes such as the K2L gene or HA gene of the vaccinia virus are defective, the anti-cancer effect is improved by causing cell fusion of infected cells by the vaccinia virus. First, the oncolytic ability is improved by increasing the proliferation and propagation ability of the virus, and apoptosis and necrosis occur actively. Then, through fusion, ICD is induced more effectively and the infiltration of CD8 T cells to the given and non-given sides is enhanced. Finally, by improving the immune environment in the tumor on the given and non-given sides, cancer immunity becomes easier to work. That is, compared with oncolytic viruses that do not induce cell fusion, oncolytic viruses that induce cell fusion more effectively transform cold tumors where immunity is difficult to work into hot tumors that are susceptible to immune attack, thereby exerting a higher anti-cancer effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 This is a diagram showing the structure of a genetically recombinant vaccinia virus that induces cell fusion. Figure 1 A to C show the structures of VGF-LucGFP / O1L-DsRed and the gene recombinant vaccinia virus derived therefrom that induces cell fusion. Figure 1 D and E show the structures of VGF-Luc / O1L-LacZ and the cell fusion-inducing genetic recombinant vaccinia virus derived therefrom.

[0036] Figure 2 The figure shows an image of cells infected with a genetically recombinant vaccinia virus that induces cell fusion.

[0037] Figure 3-1 The figure shows an image of cells infected with a genetically recombinant vaccinia virus that induces cell fusion.

[0038] Figure 3-2 This is a graph showing the cytotoxicity of the genetically recombinant vaccinia virus that induces cell fusion.

[0039] Figure 3-3 This is a graph showing the production amount of genetically recombinant vaccinia virus that induces cell fusion.

[0040] Figure 4-1 A diagram showing images of cells infected with a genetically recombinant vaccinia virus that induces cell fusion in 10 types of tumor cells.

[0041] Figure 4-2 A graph showing the cell survival rate after infection with a genetically recombinant vaccinia virus that induces cell fusion in 10 types of tumor cells.

[0042] Figure 5-1 This is a diagram showing cell death caused by a genetically recombinant vaccinia virus that induces cell fusion. Figure 5-1 A represents apoptosis in A549. Figure 5-1 B indicates necrosis.

[0043] Figure 5-2 This is a diagram showing cell death caused by a genetically recombinant vaccinia virus that induces cell fusion. Figure 5-2 A represents apoptosis in CT26. Figure 5-2 B indicates necrosis.

[0044] Figure 6 This is a graph showing immunogenic cell death (ICD) caused by genetically recombinant vaccinia virus that induces cell fusion. Figure 6 A represents the ICD of A549. Figure 6 B represents the ICD of CT26.

[0045] Figure 7 Diagram showing experimental strains of syngeneic model mice. Figure 7 A indicates that the virus is directly administered to a unilateral tumor. Figure 7 B indicates the administration and testing schedule.

[0046] Figure 8-1 A graph showing the distribution of proliferation of genetically recombinant vaccinia viruses that induce cell fusion in allogeneic transplant model mice.

[0047] Figure 8-2 Graphs showing quantification of proliferation of genetically recombinant vaccinia viruses that induce cell fusion in syngeneic mouse models. Figure 8-2 A represents the proliferation of vaccinia virus in the administered side, Figure 8-2 B shows the proliferation of vaccinia virus in the non-administered side.

[0048] Fig. 9 Graph showing tumor volume after treatment with genetically recombinant vaccinia virus that induces cell fusion in syngeneic model mice. Fig. 9 A represents the tumor volume on the administration side, Fig. 9 B shows the tumor volume on the non-administered side.

[0049] Figure 10-1 A graph showing the results of immunological analysis after treatment with a genetically recombinant vaccinia virus that induces cell fusion in allogeneic transplant model mice.

[0050] Figure 10-2 A graph showing the results of immunological analysis after treatment with a genetically recombinant vaccinia virus that induces cell fusion in allogeneic transplant model mice.

[0051] Fig.11 A graph showing tumor volume after treatment with a genetically recombinant vaccinia virus that induces cell fusion in a CD8-inhibited syngeneic model mouse. Fig.11 A represents the control result of isotype control. Fig.11 B shows the results of administration of anti-CD8 antibody. Fig.11 A and Fig.11The graph on the left side of B shows the results on the administration side, and the graph on the right side shows the results on the non-administration side.

[0052] Fig.12 Diagram showing experimental strains of syngeneic model mice at the advanced stage. Fig.12 A indicates that the virus is directly administered to a unilateral tumor. Fig.12 B indicates the administration and testing schedule.

[0053] Figure 13-1 A graph showing the distribution of proliferation of genetically recombinant vaccinia viruses that induce cell fusion in progressive syngeneic transplant model mice.

[0054] Figure 13-2 Graphs showing the quantification of the proliferation of genetically recombinant vaccinia viruses that induce cell fusion in progressive syngeneic transplant mice.

[0055] Fig.14 Graph showing tumor volume after treatment with genetically recombinant vaccinia virus that induces cell fusion in progressive syngeneic model mice.

[0056] Figure 15-1 This is a diagram showing the structure of vaccinia virus that has both cell fusion and tumor targeting capabilities.

[0057] Figure 15-2 This is a graph showing the survival rate of cells infected with vaccinia virus having both cell fusion ability and tumor targeting ability.

[0058] Figure 15-3 This is a graph showing the survival rate of cells infected with vaccinia virus having both cell fusion ability and tumor targeting ability.

[0059] Figure 15-4 It is a diagram showing immunogenic cell death after infection with vaccinia virus having both cell fusion and tumor targeting abilities.

[0060] Figure 15-5 It is a diagram showing immunogenic cell death after infection with vaccinia virus having both cell fusion and tumor targeting abilities.

[0061] Fig.16 This is a summary diagram showing the mechanism of improving the anti-cancer effect by using oncolytic viruses that induce cell fusion.

[0062] Fig.17 A diagram showing the experimental system of the syngeneic transplant model mice in combination with anti-PD-1 antibodies. Fig.17 A indicates that the virus is directly administered to a unilateral tumor. Fig.17 B indicates the administration and testing schedule.

[0063] Fig.18A graph showing tumor volume after treatment with a genetically recombinant vaccinia virus that induces cell fusion in a mouse syngeneic transplant model in combination with an anti-PD-1 antibody. Fig.18 A represents the result when anti-PD-1 antibody was not used. Fig.18 B shows the results when anti-PD-1 antibody was used in combination. Fig.18 A and Fig.18 The graph on the left side of B shows the results on the administration side, and the graph on the right side shows the results on the non-administration side.

[0064] Fig.19 A graph showing the survival rate after treatment with a genetically recombinant vaccinia virus that induces cell fusion in a syngeneic transplant model mouse in combination with an anti-PD-1 antibody.

[0065] Fig. 20 The graph shows the tumor volume after tumors were re-transplanted into mice whose tumors had been relieved using genetically recombinant vaccinia virus that induces cell fusion and anti-PD-1 antibodies. DETAILED DESCRIPTION

[0066] Hereinafter, the present invention will be described in detail.

[0067] The vaccinia virus of the present invention is a vaccinia virus mutated to have cell fusion ability. Here, cell fusion ability means that when the vaccinia virus infects a cell, it can cause cell fusion between infected cells. The vaccinia virus mutated to have cell fusion ability is a vaccinia virus in which the function of a gene that suppresses the cell fusion ability originally possessed by the vaccinia virus is defective, or a gene that promotes cell fusion is inserted and expressed.

[0068] As genes originally possessed by vaccinia virus that participate in cell fusion and inhibit cell fusion ability, K2L gene and HA (A56R) gene can be cited. The vaccinia virus of the present invention is defective in the function of K2L gene or HA gene, or K2L gene and HA gene, so that the phenotype is changed to have cell fusion ability. As shown in FIG. 8 on page 5159 of Wagenaar et al., Journal of Virology, Vol. 82, No. 11, June 2008, p. 5153-5160, in infected cells of vaccinia virus, the complex of HA (A56R) protein and K2L protein is fixed on the cell membrane via the transmembrane region of HA. The invasion fusion complex (EFC) composed of multiple viral proteins (A21L, A28L, G3L, H2R, J5L, L5R) is synergistically fixed on the membrane of mature virus together with viral proteins G9R and A16L. It is believed that G9R and A16L inhibit the fusion between the virus and the infected cell by acting on HA and K2L on the cell membrane. Thus, due to the dysfunction of HA and K2L, cell fusion can be induced without the inhibitory function. Therefore, as genes originally possessed by the vaccinia virus that participate in cell fusion and inhibit cell fusion ability, in addition to K2L or HA encoding viral proteins, A16L, A21L, A25L, A26L, A28L, G3L, G9R, H2R, J5L, L5R genes, etc. can also be cited. For example, for G9R, by mutating the 44th H to Y, even if the molecule that inhibits fusion is normal, fusion will be induced. Therefore, by making one or more of these functions defective or introducing mutations, cell fusion can be induced or enhanced. As an example of a combination, K2L can be defective and the 44th H of G9R can be mutated to Y, etc.

[0069] There are many known viral proteins with fusion ability, which can be expressed by inserting the gene into a virus containing different oncolytic viruses to mutate with cell fusion ability. As such a gene, genes encoding H (hemagglutinin) protein and F (fusion) protein from measles virus can be cited. Further, as shown in the specification of U.S. Patent No. 7,635,752, it is also possible to cause fusion with specific cells by the modification of the H gene, and by expressing it in adenovirus or vesicular stomatitis virus (VSV), it has also been shown that it can be applied to the treatment of cancer (Nakamura et al., NATURE BIOTECHNOLOGY, VOLUME 22, NUMBER 3, MARCH 2004, pp.331-336). In addition, the gene encoding the GaLV envelope derived from the gibbonape leukemia virus (GaLV) can also be cited, and by expressing it in herpes virus, adenovirus, and lentivirus, it has also been proven to be applicable to cancer treatment (Krabee et al., Cancers 2018, 10, 216; doi: 10.3390 / cancers10070216).

[0070] Other reports include VSV expressing FAST protein derived from reovirus, adenovirus expressing HIV envelope derived from HIV, VSV expressing F protein derived from Newcastle disease virus (NDV), and adenovirus expressing F protein derived from SV5 (Krabee et al., Cancers 2018, 10, 216; doi: 10.3390 / cancers10070216).

[0071] That is, examples of genes that promote cell fusion include a gene encoding a FAST protein derived from reovirus, a gene encoding an HIV envelope derived from HIV, a gene encoding an F protein derived from NDV, a gene encoding an F protein derived from SV5, and the like.

[0072] The K2L gene is known as a serine protease inhibitor, but its function is still unclear. The HA gene is a glycoprotein induced on the surface of infected cells and is known as a hemagglutinin. The nucleotide sequence of the wild-type K2L gene is shown in SEQ ID NO: 20, and the nucleotide sequence of the wild-type HA gene is shown in SEQ ID NO: 21.

[0073] The functional defect of the K2L gene or HA gene of the vaccinia virus means that the K2L gene or HA gene is not expressed, or even if the expressed protein is expressed, the normal function of the K2L protein or HA protein cannot be retained. In order to make the function of the K2L gene or HA gene of the vaccinia virus defective, all or part of the K2L gene or HA gene can be deleted. In addition, the gene can be mutated by replacing, deleting or adding bases so that the normal K2L protein or HA protein cannot be expressed. In addition, a foreign gene can be inserted into the K2L gene or HA gene. It should be noted that although cell fusion is caused by defects in K2L and HA, the cell fusion caused by the present invention is very important for the anti-cancer effect, and it can also be a defect in viral genes other than these.

[0074] The functional defect of a gene can be, for example, performed by known genome editing, homologous recombination, RNA interference, antisense, gene insertion, artificial sudden mutation, PTGS using a viral vector, etc. In the present invention, when a gene cannot express a normal gene product due to deletion or mutation, it is said that the gene is defective.

[0075] Homologous recombination refers to the phenomenon that two DNA molecules in a cell recombinate with each other through the same nucleotide sequence. It is a recombination method often used for viruses with huge genomic DNA such as vaccinia virus. First, by taking the sequence of the K2L gene or HA gene site of the vaccinia virus as the target as the central cutting form, a plasmid (called a transfer vector) connected with other DNA is constructed. If it is introduced into a cell infected with vaccinia virus, the exposed viral DNA and the same sequence part on the transfer vector are replaced during the viral replication process, and the DNA sandwiched therein is integrated into the target gene of the viral genome, so that the gene is functionally defective. As the cells used at this time, BSC-1 cells, HTK-143 cells, Hep2 cells, MDCK cells, Vero cells, HeLa cells, CV1 cells, COS cells, RK13 cells, BHK-21 cells, primary rabbit kidney cells, etc. can be used to infect vaccinia virus. In addition, the introduction of the vector into the cell can be carried out by known methods such as calcium phosphate method, cationic ribosome method, electroporation method, etc.

[0076] Genome editing is a method that uses site-specific nucleases to modify target genes. As a method for genome editing, depending on the nuclease used, there can be mentioned the ZFN (zinc finger nuclease) method (Urnov, Fyodor D. et al., Natur, Vol 435, 2 June 2005, pp. 642-651), the TALEN (TALE nuclease) method (Mahfouz, Magdy M et al., PNAS February 8, 2011, 108 (6), pp. 2623-2628), CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) / Cas9 (Crispr Associated protein 9) (Jinek, Martin, et al., Science, Vol 337, 17 August 2012, pp. 816-821), CRISPR / Cas3 and other methods using the CRISPR / Cas system, etc. These methods also include methods of modifying nucleases such as methods using nickase-modified Cas. Among them, the method using the CRISPR / Cas9 system is preferred. In the CRISPR / Cas9 system, any sequence is cut by guide RNA (crRNA, tracrRNA) and Cas9 as a nuclease, and the guide RNA contains a sequence complementary to the target sequence of the gene whose function is defective by cutting. After the genome is cut, it is repaired by NHEJ (non-homologous end joining), inducing base defects, etc., so that the gene can be knocked out. Alternatively, after the genome is cut, by HDR (homologous recombination repair), it is possible to induce mutations in the target gene by homologous recombination. When the GBSS gene and / or SBE gene are destroyed by genome editing, the target sequence in the gene is selected, and the sequence of the guide RNA containing a sequence complementary to the sequence is designed. The base length of the guide RNA is preferably 20 or more. When the CRISPR / Cas9 system is used for genome editing, it is sufficient to co-express the Cas9 protein and the guide RNA, for example, a vector that co-expresses the two can be introduced. Genome editing using CRISPR / Cas9 can be performed using commercially available CRISPR / Cas9 tools.

[0077] The strain of vaccinia virus used to prepare the vaccinia virus of the present invention is not limited, but examples thereof include Lister strain, LC16 strain constructed from Lister strain, LC16m0 strain, LC16m8 strain (Hashizume Tsuyoshi, Clinical and Viral Science vol. 3, No. 3, 269, 1975, etc.), New York City Board of Health (NYBH) strain, Wyeth strain, Copenhagen strain, Western Reserve (WR) strain, Modified Vaccinia Ankara (MVA) strain, EM63 strain, Ikeda strain, Dalian strain, Tian Tan strain, etc. The LC16mO strain is a strain produced from the Lister strain via the LC16 strain, and the LC16m8 strain is a strain produced further from the LC16mO strain in which a frameshift mutation was found in the B5R gene encoding the viral membrane protein, and the protein is expressed and no longer functions, thereby becoming an attenuated strain (Protein Nuclease, Vol. 48 No. 12 (2003), p. 1693-1700).

[0078] From the point of view of establishing safety when administered to humans, the vaccinia virus used in the present invention is preferably attenuated and non-pathogenic. As such an attenuated strain, a strain in which the B5R gene is partially or completely deleted can be cited. The B5R gene is present on the protein encoding the envelope of the vaccinia virus, and the B5R gene product is involved in the infection and proliferation of the virus. The B5R gene product is present on the surface of infected cells and on the envelope of the virus. When the virus infects and spreads to adjacent cells or other parts of the host body, it plays a role in improving the infection efficiency and is also involved in the plaque size and host range of the virus. If the B5R gene is deleted, the plaque size is reduced when infecting animal cells, and the size of the pustule is also reduced. In addition, the skin proliferation ability is reduced and the skin pathogenicity is reduced. The gene product of the B5R gene of the vaccinia virus in which the B5R gene is partially or completely deleted does not have its normal function, the skin proliferation is also reduced, and no side effects occur when administered to humans. As an attenuated strain with a B5R gene deletion, for example, the m8Δ strain (also referred to as the LC16m8Δ strain) constructed by completely deleting the B5R gene from the above-mentioned LC16m8 strain can be cited. In addition, the mOΔ strain (also referred to as the LCmOΔ strain) constructed by completely deleting the B5R gene from the LC16mO strain can also be used. These attenuated vaccinia virus strains that partially or completely lack the B5R gene are described in International Publication No. WO2005 / 054451 and can be obtained based on the description. Whether the vaccinia virus partially or completely lacks the B5R gene, resulting in a functional loss of the B5R protein, can be judged, for example, by the following indicators: the size of the plaques formed when infecting RK13 cells, the size of the pustule, the viral proliferation in Vero cells, the skin pathogenicity in rabbits, etc. In addition, the gene sequence of the vaccinia virus can also be investigated.

[0079] The vaccinia virus with the B5R gene expresses the B5R gene in cancer cells, and through the action of the B5R protein, the cancer cells are killed. Therefore, the vaccinia virus used in the present invention is expected to express a complete B5R gene. When using a vaccinia virus that does not have a B5R gene, is attenuated and has established safety as described above, the complete B5R gene is re-introduced into the vaccinia virus lacking the B5R gene. When using a vaccinia virus that partially or completely lacks the B5R gene, the B5R gene can also be inserted into the vaccinia virus genome for use. The insertion of the B5R gene into the vaccinia virus can be carried out by any method, for example, by a known homologous recombination method. In addition, in this case, the position of inserting the B5R gene can be between the B4R gene and the B6R gene where the B5R gene originally exists, or it can be any site in the genome of the vaccinia virus. Further, the B5R gene can also be pre-constructed as a DNA construct and introduced into the vaccinia virus.

[0080] By causing defects in the K2L gene or HA gene of the vaccinia virus, the function of K2L or HA does not work, thereby improving the proliferation and transmission ability of the virus, thereby improving the oncolytic ability, and inducing cell death of infected cancer cells. Here, cell death includes apoptosis and necrosis. In addition, cell fusion of infected cancer cells is caused. By causing cell fusion, the ability to induce immunogenic cell death (ICD: Immunogenic cell death) is improved. As a result, CD8 T cells actively infiltrate cancer cells and attack cancer cells. Further, systemic anti-cancer immune activity is improved. In addition, it was found that immunosuppressive cells such as Treg, TAM, and MDSC were reduced.

[0081] As a result, the K2L gene or HA gene of the vaccinia virus becomes defective, the function of K2L or HA is ineffective, and the anti-cancer effect of the vaccinia virus is enhanced.

[0082] As described above, the vaccinia virus improves its anti-cancer effect by causing cell fusion in infected cells, and its anti-cancer effect and ICD induction ability are improved regardless of whether there is tumor specificity. However, when the vaccinia virus is tumor specific, the anti-cancer effect is synergistically improved. Therefore, the vaccinia virus used in the present invention is preferably an oncolytic virus (oncolytic virus) that has tumor cell-specific cytolysis and can infect cancer cells and cause cancer cells to die. As this method, the following genetic modification can be added: the function of a specific protein is defective and the expression of a specific gene or protein is inhibited.

[0083] Examples of such genes include the hemagglutinin (HA) gene; the thymidine kinase (TK) gene; the F fragment; the F3 gene; the vaccinia virus growth factor (VGF) gene (U.S. Patent Application Publication No. 2003 / 0031681); O1L; the hemorrhagic region or the type A inclusion region (U.S. Patent No. 6,596,279); the Hind III F, F13L or Hind III M region (U.S. Patent No. 6,548,068); the A33R, A34R or A36R gene (Katz et al., J. Virology 77: 12266-12275 (2003)); the SalF7L gene (Moore et al., EMBO J. 1992 11: 1973-1980); the N1L gene (Kotwal et al., Virology 1989 11: 1989-1990); 171:579-58); M1 gene (Child et al., Virology, 1990174:625-629); HR, HindIII-MK, HindIII-MKF, HindIII-CNM, RR or BamF region (Lee et al., J Virol. 1992 66:2617-2630); C21L gene (Isaacs et al., Proc Natl Acad Sci USA. 199289:628-632), etc. Among these genes, VGF gene, O1L gene, TK gene, HA gene, and F fragment are preferred.

[0084] In addition, multiple genetic modifications may be combined. Examples of multiple genetic modifications include the following modifications.

[0085] · Functional defects of TK, HA and F14.5L (Cancer Research, 2007, Vol. 67, p. 10038-10046) · Functional defects of TK and B18R (PLoS Medicine, 2007, Vol. 4, p. e353)

[0086] · Functional defects of TK and ribonucleotide reductase (PLoS Pathogens, 2010, Vol. 6, p. e1000984)

[0087] · SPI-1 and SPI-2 functional defects (Cancer Research, 2005, Vol. 65, p. 9991-9998)

[0088] · SPI-1, SPI-2 and TK functional defects (Gene Therapy, 2007, Vol. 14, p. 638-647)

[0089] Introduction of mutations in the E3L and K3L regions (International Publication No. 2005 / 007824)

[0090] Vaccinia viruses that have defective functions of these genes and are oncolytic are called oncolytic vaccinia viruses.

[0091] A plurality of these genes may be defective. For example, both the VGF gene and the O1L gene may be defective. Vaccinia viruses defective in both the VGF gene and the O1L gene are described in International Publication No. WO2015 / 076422.

[0092] For example, if the function of the TK gene is defective, the proliferation ability of the vaccinia virus in normal cells is reduced. On the other hand, since cancer cells are rich in enzymes that compensate for the function of this gene, the proliferation ability in cancer cells will not be reduced. The reduction in the proliferation ability in normal cells means that the pathogenicity to normal cells is reduced, that is, the safety when applied to organisms is improved. In addition, when the vaccinia virus with defective functions of the two genes, VGF gene and O1L gene, infects normal cells, since ERK is not activated in normal cells, cell proliferation is not promoted, and as a result, the proliferation of the vaccinia virus is significantly reduced. On the other hand, in cancer cells, since the Ras / Raf / MEK / ERK metabolic pathway is abnormally activated, it compensates for the activation function of ERK caused by VGF and O1L of the vaccinia virus, so the vaccinia virus can proliferate. As a result, the vaccinia virus specifically proliferates in cancer cells, destroys cancer cells and causes killing.

[0093] The use of vaccinia virus having oncolytic activity synergistically enhances the ability of cancer cells to cause cell death in interaction with the increased cell fusion ability utilizing the defects of the K2L gene or the HA gene.

[0094] The defects of these genes can be corrected by the above-mentioned genome editing, homologous recombination, RNA interference method, antisense method, gene insertion method, artificial mutation method, PTGS method using viral vectors, etc.

[0095] The target cancers for cancer virus therapy using vaccinia virus are not limited, and examples include all cancers such as ovarian cancer, lung cancer, pancreatic cancer, skin cancer, stomach cancer, liver cancer, hepatocellular carcinoma, colon cancer, anal / rectal cancer, esophageal cancer, uterine cancer, breast cancer, bladder cancer, prostate cancer, testicular cancer, head and neck cancer, brain / nerve tumors, thymic cancer, lymphoma / leukemia, bone / osteosarcoma, leiomyoma, rhabdomyoma, and melanoma.

[0096] The pharmaceutical composition for treating cancer containing the vaccinia virus of the present invention contains a pharmaceutically effective dose of the vaccinia virus of the present invention as an active ingredient, and can be in the form of a sterile aqueous or non-aqueous solution, suspension or emulsion. Furthermore, it can contain pharmaceutically acceptable diluents, auxiliary agents, carriers, etc. such as salts, buffers, adjuvants, etc. Administration can be through various parenteral routes, for example, subcutaneous route, intravenous route, intradermal route, intramuscular route, intraperitoneal route, intranasal route, transdermal route. In addition, local administration to the cancer site can also be performed. The effective administration amount can be appropriately determined based on the age, gender, health and weight of the subject. For example, although not limited, for adults, each administration is about 10 2 ~10 10 Plaque forming units (PFU).

[0097] The present invention also includes a method of treating cancer, which comprises administering the above-mentioned vaccinia virus to a cancer patient.

[0098] Moreover, the vaccinia virus of the present invention may contain exogenous genes (exogenous DNA or exogenous polynucleotides). As exogenous genes (exogenous DNA or exogenous polynucleotides), marker genes, therapeutic genes encoding products with cytotoxic and immune activation effects, and further DNA encoding protein antigens such as cancer, viruses, bacteria, and protozoa can be cited. Marker genes are also called reporter genes, and fluorescent protein genes such as luciferase (LUC) genes, green fluorescent protein (Green fluorescent protein; GFP), red fluorescent protein (DsRed), β-glucuronidase (GUS) genes, chloramphenicol acetyltransferase (CAT) genes, β-galactosidase (LacZ) genes, etc. can be cited. The oncolytic vaccinia virus containing these exogenous genes can be called a vaccinia virus vector.

[0099] Therapeutic genes are genes that can be used to treat specific diseases such as cancer and infectious diseases, and examples include genes encoding tumor suppressor genes such as p53 and Rb, interleukin 1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-17, IL-18, IL-24, chemokine 2 (CCL2), CCL5, CCL19, CCL21, CXCL9, CXC L10, CXCL11, CD40L, CD70, CD80, CD137L, OX-40L, GITRL, LIGHT, α-interferon, β-interferon, γ-interferon, angiostatin, thrombospondin, endostatin, METH-1, METH-2, GM-CSF, G-CSF, M-CSF, MIP1a, FLT3L, HPGD, TRIF, DAI, genes encoding physiologically active substances such as tumor necrosis factor, genes encoding antibodies with CTLA4, PD1, PD-L1 inhibitory effects, etc. Vaccinia virus expressing luciferase and GFP can simply and quickly detect cancer cells as its infected cells. When the vaccinia virus of the present invention is used to treat cancer, the therapeutic gene for cancer can exert a cancer treatment effect simultaneously with the oncolytic property of the vaccinia virus.

[0100] By introducing DNA encoding antigens such as viruses, bacteria, protozoa and cancer as foreign genes (foreign DNA), vaccinia virus vectors introduced with foreign genes can be used as vaccines against various viruses, bacteria, protozoa and cancer. For example, antigens encoding infection protection antigens (neutralizing antigens) against human immunodeficiency virus, hepatitis virus, herpes virus, mycobacterium, malarial parasite, severe acute respiratory syndrome (SARS) virus, etc., or WT1, MART-1, NY-ESO-1, MAGE-A1, MAGE-A3, MAGE-A4, glypican-3, KIF20A, survivin, AFP-1, gp100, MUC1, PAP-10, PAP-5, TRP2-1, SART-1, VEGFR1, VEGFR2, NEIL3, MPHOSPH1, DEPDC1, FOXM1, CDH3, TTK, TOMM34, URLC10, KOC1, UBE2T, TOPK, ECT2, MESOT, etc. are introduced. Genes of cancer antigens such as HELIN, NKG2D, P1A, 5T4, B7-H6, BCMA, CD123, CD133, CD138, CD171, CD19, CD20, CD22, CD23, CD30, CD33, CD38, CD44, CEA, cMet, CS1, EGFR, EGFRvIII, EphA2, ErbB2, FAP, FR-α, HER2, IL13Ra2, MUC1, MUC16, NKG2D, PSCA, PSMA, ROR1, TARP, DLL3, PRSS21, claudin 18.2, claudin 18, CAIX, L1-CAM, FAP-α, CTAG1B, FR-α and other proteins, and glycolipids such as GD2 and GM2 can be used.

[0101] These foreign genes can be introduced, for example, by using a homologous recombination method. Homologous recombination can be performed according to the above method. For example, a plasmid (transfer vector) is prepared in which the foreign gene to be introduced is connected to the DNA sequence of the site to be introduced, and it is introduced into the cells infected with the vaccinia virus. The region for introducing the foreign gene is preferably in a gene that is not essential for the life cycle of the vaccinia virus.

[0102] In addition, when introducing a foreign gene, it is desirable to connect it upstream of the foreign gene in a form in which a suitable promoter function is exerted. The promoter is not limited, but the above-mentioned PSFJ1-10, PSFJ2-16, p7.5K promoter, p11K promoter, T7.10 promoter, CPX promoter, HF promoter, H6 promoter, T7 hybrid promoter, etc. can be used. The method of introducing a foreign gene into the vaccinia virus vector of the present invention can be carried out by a known method for constructing a recombinant vaccinia virus vector, for example, according to the descriptions in the supplementary volume Experimental Medicine: Experimental Methods for Gene Introduction and Expression Analysis (Supplementary Experimental Medicine Operation Guide Series: Experimental Methods for Gene Introduction and Expression Analysis), edited by Saito Izumi et al., Yodosha (published on September 1, 1997), or DNA Cloning 4 - Mammalian System - (2nd edition) TaKaRa, EMBO Journal (1987, Vol. 6, p. 3379-3384), edited by DM Glover et al., with Kato Ikunoshin as the translation supervisor.

[0103] The present invention also includes the combined use of vaccinia virus with cell fusion ability and immune checkpoint inhibitors for treatment.

[0104] Immune checkpoint inhibitors include anti-PD-1 (programmed cell death receptor 1, Programmed cell death 1) antibodies, anti-PD-L1 (programmed cell-death ligand 1, Programmed cell-death ligand 1) antibodies, anti-CTLA-4 antibodies, anti-PD-L2 antibodies, anti-LAG-3 antibodies, PD-1 inhibitors, PD-L1 inhibitors, etc. Among these, anti-PD-1 antibodies and anti-PD-L1 antibodies are preferred. As anti-PD-1 antibodies, Nivolumab, Pembrolizumab, Spartalizumab, Cemiplimab, Tislelizumab, Camrelizumab, etc. can be cited, and as anti-PD-L1 antibodies, Avelumab, Durvalumab, Atezolizumab, etc. can be cited.

[0105] Immune checkpoint inhibitors can be administered by known methods. The dosage of immune checkpoint inhibitors varies depending on symptoms, age, weight, and other conditions, for example, 0.001 mg to 100 mg is administered every few days, weeks, or months by subcutaneous injection, intramuscular injection, intravenous injection, etc.

[0106] Immune checkpoint inhibitors may include carriers, diluents, excipients, etc. commonly used in the field of preparations. For example, as carriers and excipients for tablets, lactose, magnesium stearate, etc. can be used. As aqueous solutions for injection, isotonic solutions containing physiological saline, glucose and other adjuvants can be used, and polyols such as alcohol and propylene glycol, non-ionic surfactants and other solubilizing agents can also be used in combination. As oily liquids, sesame oil, soybean oil, etc., solubilizing agents such as benzyl benzoate and benzyl alcohol can also be used in combination.

[0107] The vaccinia virus with cell fusion ability and the immune checkpoint inhibitor of the present invention can play a synergistic effect in cancer treatment. The cancer treatment effect when the vaccinia virus with cell fusion ability and the immune checkpoint inhibitor are used in combination is significantly higher than the cancer treatment effect when the vaccinia virus with cell fusion ability or the immune checkpoint inhibitor is used alone.

[0108] Administration of the vaccinia virus with cell fusion ability of the present invention can be performed simultaneously or separately or continuously with the administration of the immune checkpoint inhibitor. Administration of the vaccinia virus with cell fusion ability can also be performed before or after the administration of the immune checkpoint inhibitor. Preferably, administration of the vaccinia virus with cell fusion ability is performed before the administration of the immune checkpoint inhibitor.

[0109] The present invention also includes a combination, a combined preparation or a combined drug kit containing a vaccinia virus having cell fusion ability and an immune checkpoint inhibitor.

[0110] The present invention also includes a method for combining a vaccinia virus having cell fusion ability and an immune checkpoint inhibitor in the preparation of a drug for treating cancer.

[0111] The present invention also includes a drug containing a vaccinia virus having cell fusion ability and an immune checkpoint inhibitor.

[0112] The present invention further includes vaccinia viruses having cell fusion competence for use in combination with immune checkpoint inhibitors.

[0113] Example

[0114] The present invention is specifically described by the following examples, but the present invention is not limited to these examples.

[0115] Example 1 Structure of vaccinia virus with cell fusion ability

[0116] In order to insert an exogenous gene expression unit different from the VGF gene and the O1L gene into the mitogen-activated protein kinase-dependent gene recombinant vaccinia virus (International Publication No. WO2015 / 076422) in which both VGF and O1L are inactive, the BFP gene region was amplified using two primers (SEQ ID NO: 1 and SEQ ID NO: 2) using the DNA of pTagBFP-N (FP172, Evrogen) as a template. Each PCR product was digested with restriction endonucleases SfiI and EcoRI, cloned into the same restriction endonuclease site of the pTK-SP-LG vector (International Publication No. WO2015 / 076422), and pTNshuttle / TK-SP-BFP was constructed by connecting BFP downstream of the synthetic vaccinia virus promoter (Hammond JM. et al., Journal of Virological Methods. 1997; 66(1): 135-138). Next, pTNshuttle / TK-SP-BFP was digested with restriction endonucleases SphI and EcoRI, and after blunt-end treatment, the SP-BFP fragment was cloned into the site of pUC19-VGF vector (International Publication No. WO2015 / 076422) digested with restriction endonuclease AccI and blunt-end treated, or into the site of pUC19-O1L vector (International Publication No. WO2015 / 076422) digested with restriction endonuclease XbaI and blunt-end treated, to construct a shuttle vector pTNshuttle / VGF-ST-BFP for expressing BFP in the opposite direction to VGF or pTNshuttle / O1L-SP-BFP for expressing BFP in the opposite direction to O1L. On the other hand, according to the same method as International Publication No. WO2015 / 076422, pUC19-O1L-P-DsRed for expressing DsRed in the same direction as O1L was constructed downstream of the p7.5K promoter instead of the synthetic vaccinia virus promoter. CV1 cells cultured in a 24-well plate to 80% confluence were infected with VGF-LucGFP / O1L-DsRed at MOI = 0.1 to 0.5 and adsorbed at room temperature for 1 hour. Then, the transfer vector plasmid pTNshuttle / O1L-SP-BFP mixed with FuGENE HD (Roche) was added to the cells according to the operating manual and allowed to be taken up, and cultured at 37°C for 2 to 3 days. After the cells were collected and frozen and thawed, they were ultrasonically treated, and BSC1 cells that had basically reached confluence were appropriately diluted and inoculated, and Eagle MEM and 5% FBS medium containing 0.5% methylcellulose were added, and cultured at 37°C for 2 to 4 days. The culture medium was removed, and the plaques expressing BFP were scraped with a pipette tip and suspended in Opti-MEM culture medium (Invitrogen).This operation was further repeated three or more times using BSC1 cells to purify plaques. The plaque suspension selected after plaque purification was subjected to ultrasonic treatment, and then 200 μL thereof was used to extract genomic DNA using the High PureViral Nucleic Acid Kit (Roche) according to the operating manual for PCR screening. For O1L, PCR was performed using two primers (SEQ ID NO: 3 and SEQ ID NO: 4), and the nucleotide sequence of the PCR product was confirmed by direct sequencing for clones in which a PCR product of a predetermined size was detected. A virus clone VGF-LucGFP / O1L-BFP with no nucleotide sequence problems was selected, amplified using A549 cells, and then used for experiments to determine the virus titer using RK13 cells. Based on this vaccinia virus (VGF-LucGFP / O1L-BFP) and the transfer vector plasmid DNA (pUC19-O1L-P-DsRed), and using the expression of DsRed as an indicator, the recombinant virus was collected in the same manner as above to prepare VGF-LucGFP / O1L-DsRed.

[0117] In the step of making the gene recombinant vaccinia virus, viruses with cell fusion ability that are not usually seen appear at a very high frequency. Therefore, the culture medium was removed, and the plaques with fusion characteristics were scraped with a pipette tip and suspended in opti-MEM culture medium (Invitrogen). This operation was further repeated 3 or more times with BSC1 cells, and two virus clones with cell fusion ability were obtained by purifying the plaques. These two clones were sequenced directly using the next generation sequencer PacBio RSII (Pacific Bioscience) or PCR, and mutations in the K2L or HA gene were found from the obtained sequence information, and the nucleotide sequence was shown as SEQ ID NO: 5 or SEQ ID NO: 6. K2L is a gene with a total length of 1110 bp, in which the guanine at the 762nd bp was mutated to adenine. From this, it can be seen that the amino acid at position 254 mutated from tryptophan to a stop codon, and a nonsense mutation occurred. In addition, HA is a gene with a total length of 933 bp, and the adenine at the 70th bp is defective. From this, it can be seen that a frameshift mutation occurred. In summary, the two virus clones with cell fusion ability obtained were significantly higher than those of the parent virus VGF-LucGFP / O1L-DsRed (International Publication No. WO2015 / 076422) ( Figure 1 A), referred to as VGF-LucGFP / K2Lmut / O1L-DsRed and VGF-LucGFP / O1L-BFP / HAmut ( Figure 1 B and Figure 1C), after each recombinant virus was cultured in large quantities in A549 cells and purified, the virus titer was determined using RK13 cells for experimental use.

[0118] Next, the Luc2 gene region was amplified using DNA from pGL4.20 (F6751, Promega) as a template using two primers (SEQ ID NO: 7 and SEQ ID NO: 8). Each PCR product was digested with restriction endonucleases BspEI and NheI, and cloned into the AgeI and NheI restriction endonuclease sites of the pTNshuttle / VGF-SP-BFP vector in a manner that replaced the BFP gene, thereby constructing pTNshuttle / VGF-SP-Luc. On the other hand, the Escherichia coli LacZ gene (SEQ ID NO: 9) synthesized in a codon-optimized manner in H. sapiens was digested with restriction endonucleases AgeI and NheI, and cloned into the same restriction endonuclease sites of the pTNshuttle / O1L-SP-BFP vector in a manner that replaced the BFP gene, thereby constructing pTNshuttle / O1L-SP-LacZ.

[0119] In order to collect Figure 1 The recombinant vaccinia virus having a viral genome shown in B is prepared by collecting the recombinant virus in the same manner as above based on the vaccinia virus (VGF-LucGFP / O1L-DsRed or VGF-LucGF P / K2Lmut / O1L-DsRed) and the transfer vector plasmid DNA (pTNshuttle / VGF-SP-Luc) and using the disappearance of GFP expression as an indicator to prepare VGF-Luc / O1L-DsRed or VGF-Luc / K2Lmut / O1L-DsRed. Based on the vaccinia virus (VGF-Luc / O1L-DsRed or VGF-Luc / K2Lmut / O1L-DsRed) and the transfer vector plasmid DNA (pTNshuttle / O1L-SP-LacZ), the recombinant virus is collected in the same manner as above based on the disappearance of DsRed expression as an indicator for PCR screening. PCR was performed using two primers (SEQ ID NO: 10 and SEQ ID NO: 11) for VGF and two primers (SEQ ID NO: 12 and SEQ ID NO: 13) for K2L, and the nucleotide sequence of the PCR product was confirmed by direct sequencing for clones in which a PCR product of a predetermined size was detected. Virus clones VGF-Luc / O1L-LacZ or VGF-Luc / K2Lmut / O1L-LacZ ( Figure 1D and E). Each recombinant virus was cultured in large quantities in A549 cells and purified, and then the virus titer was determined using RK13 cells for experimental use.

[0120] Example 2 Characteristic Analysis of Vaccinia Virus with Cell Fusion Ability

[0121] In order to compare VGF-LucGFP / O1L-DsRed, which does not have cell fusion ability, with VGF-LucGFP / K2Lmut / O1L-DsRed and VGF-LucGFP / O1L-BFP / HAmut, which have cell fusion ability, infection with each virus was performed. First, various cancer cells (human ovarian cancer RMG1 cells, human colon cancer CaCO2 cells, human lung cancer A549 cells, mouse colon cancer CT26 cells) were plated in a 96-well plate at 2.0×10 RMG1 and CaCO2. 4 / hole, A549 is 1.0×10 4 / hole, CT26 is 6.0×10 3 / wells were inoculated, and when the confluence reached 80% after culturing for 24 hours, VGF-LucGFP / O1L-DsRed, VGF-LucGFP / K2Lmut / O1L-DsRed or VGF-LucGFP / O1L-BFP / HAmut was adjusted to RMG1, CaCO2, A549 with MOI=0.1, and CT26 with MOI=10 for infection. 72 hours after the infection, the infection image was observed using BZ-X700 (KEYENCE). The results showed that compared with VGF-LucGFP / O1L-DsRed, VGF-LucGFP / K2Lmut / O1L-DsRed and VGF-LucGFP / O1L-BFP / HAmut were infected at the same time as the fusion cells in various cancer cells ( Figure 2 ).

[0122] Next, VGF-LucGFP / O1L-DsRed and VGF-LucGFP / K2Lmut / O1L-DsRed were used to verify whether changes in cell fusion affected the anticancer effect. 4 A549 cells were inoculated per well, and each virus solution was used to infect cells at MOI = 0.01, 0.1, and 1 when the confluence reached 80% to 90% after culturing for 24 hours. The infection images were observed using BZ-X700 (KEYENCE) 72 hours after infection. The results showed that VGF-LucGFP / K2Lmut / O1L-DsRed was infected at the same time as the fused cells in an MOI-dependent manner compared to VGF-LucGFP / O1L-DsRed. Figure 3-1In the figure, the infected cell images are shown. In addition, the cell viability was measured using CellTiter96 (registered trademark) Aqueous Non-radioactive Cell Proliferation Assay (Promega) 72 hours after infection. The results showed that compared with VGF-LucGFP / O1L-DsRed, VGF-LucGFP / K2Lmut / O1L-DsRed showed a decrease in cell viability at MOI = 0.1 and 1, indicating an improved anticancer effect. Figure 3-2 Cytotoxicity was expressed as cell survival rate. In addition, in order to investigate whether the amount of virus produced changes when cell fusion changes, the amount of virus produced by VGF-LucGFP / O1L-DsRed and VGF-LucGFP / K2Lmut / O1L-DsRed was compared by virus titer measurement (titration). First, 5.0×10 4 Human lung cancer cell line A549 cells were inoculated as hosts in / well, and when the confluence reached 60% to 80% after culturing for 24 hours, each virus solution was infected at MOI = 0.1. Cells and supernatant were collected by scraping 24, 48, and 72 hours after infection, and the cells were broken by freeze-thaw and ultrasonic treatment. After centrifugation at 2000 rpm at 4°C for 10 minutes, the supernatant was collected. RK13 cells were inoculated in the titer determination of the virus, and the dilution rate was changed according to the assumed virus titer. The titer was determined by stepwise dilution (10 dilution) of RK13 inoculated when the confluence reached 80% in the 12-well plate. -1 ~10 -5 The cells were infected with each virus at a concentration of 100 times (fold), and cultured for 3 days in Eagle MEM containing 0.8% methylcellulose and 5% FBS. The virus titer was calculated by measuring the number of virus plaques formed. As a result, it was confirmed that there was no difference in the amount of virus produced between VGF-LucGFP / O1L-DsRed and VGF-LucGFP / K2Lmut / O1L-DsRed. Figure 3-3 The amount produced is expressed in titer.

[0123] Example 3 Anticancer Effect of Vaccinia Virus with Cell Fusion Ability

[0124] Next, the survival rates of cells other than A549 were investigated using various human and mouse cancer cells. Human ovarian cancer cells (SKOV3: 2.0×10 4 / well), human pancreatic cancer cells (Panc1: 2.0×10 4 / well), human colon cancer cells (CaCO2: 2.0×10 4 / well), human breast cancer cells (MDA-MB-231: 2.0×104 / well), human lung cancer cells (A549: 1.0×10 4 / well), human prostate cancer cells (PC3: 2.5×10 4 / well), human skin cancer cells (A431: 2.0×10 4 / well), mouse melanoma cells (B16-F10: 1.5×10 4 / well), mouse colon cancer cells (CT26: 1.0×10 4 / well) and mouse lung cancer cells (TC1: 4.0×10 3 / well) were inoculated in a 96-well plate, and after culturing at 37°C for 24 hours, each virus solution of VGF-LucGFP / O1L-DsRed or VGF-LucGFP / K2Lmut / O1L-DsRed was infected at an MOI of 0.1 for Panc1, CaCO2, MDA-MB-231, A549 and A431, an MOI of 1 for SKOV3 and PC3, and an MOI of 5 for B16-F10, CT26 and TC1 (n=3). Then, the cell viability was measured by CellTiter 96 (registered trademark) Aqueous Non-radioactive Cell Proliferation Assay (Promega) 48 hours after TC1 and 72 hours after infection.

[0125] At this time, if the infection pattern is observed, cell fusion infection patterns can be confirmed in VGF-LucGFP / K2Lmut / O1L-DsRed, showing that the infection pattern is different from that of VGF-LucGFP / O1L-DsRed in a wide range of cancers ( Figure 4-1 ). Furthermore, in terms of cell survival rate, it was found that VGF-LucGFP / K2Lmut / O1L-DsRed was significantly reduced compared with VGF-LucGFP / O1L-DsRed by t-test (SKOV3: **P=0.0021, Panc1: ***P-=0.0003, CaCO2: ***P<0.0001, MDA-MB-231: ***P=0.0004, A549: ***P<0.0001, PC3: *P=0.0284, A431: *P=0.0480, B16-F10: ***P=0.0004, CT26: **P=0.0030, TC1: ***P-=0.0006). This shows that the anti-tumor effect of VGF-LucGFP / K2Lmut / O1L-DsRed is improved in a wide range of cancers ( Figure 4-2 ).

[0126] Example 4 In vitro analysis of the anticancer effect mechanism of vaccinia virus with cell fusion ability

[0127] Apoptotic / Necrotic / Healthy Cells Detection Kit (Takara Bio) was used to verify whether apoptosis and necrosis occurred significantly in human lung cancer cell line (A549) and mouse colon cancer cell line (CT26). First, A549 or CT26 was plated in a 96-well plate at 1.0×10 4 / well, and after culturing at 37°C for 24 hours, each virus solution of VGF-Luc / O1L-lacZ or VGF-Luc / K2Lmut / O1L-lacZ was infected at MOI=1 for A549 and MOI=10 for CT26 (n=3). After 30 hours or 22 hours from infection, the test was performed using the above kit, and the image was taken with BZ-X700 (KEYENCE), and then quantified. As a result, in both A549 and CT26, the number of cells detected as apoptosis of VGF-Luc / K2Lmut / O1L-lacZ was significantly increased in the t test compared with VGF-Luc / O1L-lacZ (A549: *P=0.0355, CT26: *P=0.0264). Furthermore, not only apoptosis but also cells detected as necrosis were dominantly increased in the t-test (Figure 5) (A549: *P=0.0181, CT26: *P=0.0264). Furthermore, immunogenic cell death (ICD), which is considered important in the induction of anti-tumor immunity, was also verified. As the mechanism of immune induction using ICD, the extracellular release of HMGB1 and the cell surface exposure of calreticulin have been reported. This time, extracellular HMGB1 was quantified by HMGB1 ELISA Kit II (Shino-Test). A549 or CT26 were plated in a 24-well plate at 5.25×10 4 A549 cells were seeded at 3.15 × 10 4 CT26 was inoculated per well, and after culturing at 37°C for 24 hours, each virus solution of VGF-Luc / O1L-lacZ or VGF-Luc / K2Lmut / O1L-lacZ was infected at MOI=1 for A549 and MOI=5 for CT26 (n=3). Cell supernatants were collected 60 hours after infection and ELISA was performed. The results showed that the extracellular release of HMGB1 of VGF-Luc / K2Lmut / O1L-lacZ significantly increased compared with VGF-Luc / O1L-lacZ in both A549 and CT26, which could be confirmed by t-test ( Figure 6 )(A549: ***P=0.0006, CT26: ***P=0.0004). These results indicate that the enhancement of apoptosis and necrosis induction ability and the enhancement of antitumor immunity induction ability by ICD in VGF-Luc / K2Lmut / O1L-lacZ contribute to the enhancement of anticancer effect.

[0128] Example 5 In vivo therapeutic effect of vaccinia virus with cell fusion ability

[0129] Next, using the allogeneic transplant model, the proliferation and spread of the virus in vivo and the therapeutic effects of the virus were studied.

[0130] Mouse colon cancer cell line (CT26) was cultured at 5.0×10 5 The cells were transplanted subcutaneously on both sides of the abdomen of BALB / cAjcl mice and the tumors were allowed to grow for 5 or 6 days to a size of 42 to 94 mm. 3( Average 60mm 3 )( Figure 7 A). After tumor growth, VGF-Luc / O1L-lacZ and VGF-Luc / K2Lmut / O1L-lacZ were added every other day for 3 times at 5.0×10 7 PFU was directly administered into the unilateral tumor (days 0, 2, and 4). In addition, the viral FLuc luminescence (≒viral proliferation and spread) was non-invasively detected by administering Vivo Glo Luciferin (Promega) and using an in vivo imaging system (Berthold, NightSHADE LB985) (days 1, 3, 5, and 7) ( Figure 7 B). Figure 8-1 The results of viral FLuc (firefly luciferase) detection 3 days after virus administration are shown in the figure. On the 3rd day after virus administration, on the virus-administered side, the viral FLuc expression signal of VGF-Luc / K2Lmut / O1L-lacZ was higher than that of VGF-Luc / O1L-lacZ. On the other hand, even when the virus was administered to the non-virus-administered side, no viral signal could be confirmed. Furthermore, when quantifying viral FLuc expression, it was found that there was a significant difference in the two-way ANOVA statistical analysis on the 3rd day after virus administration on the administered side (*P<0.05) ( Figure 8-2). Thus, it was confirmed that VGF-Luc / K2Lmut / O1L-lacZ actively carried out virus proliferation and propagation in vivo compared with VGF-Luc / O1L-lacZ. Next, the therapeutic effect of the virus was studied by measuring the tumor diameter. The results showed that compared with virus-unadministered (PBS) mice and VGF-Luc / O1L-lacZ virus-administered mice, tumor proliferation on the virus-administered side and the non-administered side of VGF-Luc / K2Lmut / O1L-lacZ virus-administered mice was inhibited. Furthermore, after 22 days, compared with the tumor volume of PBS mice and VGF-Luc / O1L-lacZ virus-administered mice, the significant difference in tumor volume between the virus-administered side and the non-administered side of VGF-Luc / K2Lmut / O1L-lacZ virus-administered mice was confirmed by two-way analysis of variance (**P<0.01, ***P<0.001)( Fig. 9 ).

[0131] Example 6 Analysis of the mechanism of therapeutic effect of vaccinia virus with cell fusion ability in vivo

[0132] Next, in order to analyze the mechanism of the improvement of the therapeutic effect in vivo, immunological analysis was performed using flow cytometry. Mouse colon cancer cell line (CT26) was cultured at 5.0×10 5 The cells were transplanted subcutaneously on both sides of the abdomen of BALB / cAjcl mice and the tumors were allowed to grow to 50-111 mm in 5 days. 3( Average 60mm 3 After the tumors grew, VGF-Luc / O1L-lacZ and VGF-Luc / K2Lmut / O1L-lacZ were added every other day for 3 times at 5.0×10 7 PFU was directly administered into the tumor on one side (days 0, 2, and 4). Tumors on both sides of the abdomen were collected in serum-free RPMI 5 days after virus administration (day 5), and tumor tissue was dissociated using mild MACS (Miltenyi Biotec). After filtering the cells with a 100 μm filter and hemolyzing them, the cells were counted and adjusted to 5.0 × 10 5The adjusted cells were blocked with Fc Block (BD Bioscience), and cell surface antigen staining and intracellular antigen staining were performed, and CD8, CD4, Treg, TAM, and MDSC were analyzed using CytoFLEX (BECKMAN COULTER). 7AAD (BECKMAN COULTER) was used for dead cell staining, CD45 (30-F11; BioLegend), CD3 (145-2C11; BioLegend), CD8 (53-6.7; BioLegend), CD4 (GK1.5; Thermo), CD25 (PC61.5; Thermo), F4 / 80 (BM8; BioLegend), CD11b (M1 / 70; BioLegend), Ly6G (1A8; BioLegend), Ly6C (AL21; BD Bioscience) were used for cell surface antigen staining, and FoxP3 (FJK-16s; Thermo) was used for intracellular antigen staining. The results of immune cell infiltration determined by immunological analysis were recorded in Figure 10-1 and 10-2 Infiltration of CD8 T cells was found to increase only in the virus-administered side due to administration of VGF-Luc / K2Lmut / O1L-lacZ, but it was significantly increased in the non-administered side compared with VGF-Luc / O1L-lacZ in the t-test (*P=0.0413). Next, infiltration of CD4 T cells was significantly reduced in VGF-Luc / K2Lmut / O1L-lacZ compared with PBS on the administered side, but there was no change on the non-administered side (**P=0.0025). In addition, in Tregs, VGF-Luc / K2Lmut / O1L-lacZ was reduced in the virus-administered side compared with PBS, but no reduction was found on the non-administered side (*P=0.0362, **P=0.0094). Furthermore, TAM was administered with VGF-luc / K2Lmut / O1L-lacZ, and both the virus-administered side and the non-administered side were significantly reduced compared with PBS (*P=0.0383, ***P=0.0002). Finally, the G-MDSC of MDSC increased significantly on the administered side due to the administration of the virus (*P=0.0179, **P=0.0051). On the other hand, M-MDSC decreased on the administered side only when VGF-Luc / K2Lmut / O1L-lacZ was administered compared with PBS (*P=0.0417). Thus, it is shown that the reduction of immunosuppressive cells such as Treg, TAM, and MDSC on the virus-administered side and the increase in the infiltration of CD8 T cells on the non-administered side are very important for the therapeutic effect.

[0133] The results of immunological analysis showed that the infiltration of CD8 T cells was important for the therapeutic effect on the side where the virus was not given, so the effect of CD8 T cells was suppressed by inhibitors. 5 The cells were transplanted subcutaneously on both sides of the abdomen of BALB / cAjcl mice and the tumors were allowed to grow to 42-128 mm in 5 days. 3( Average 60mm 3 After the tumors grew, VGF-Luc / O1L-lacZ and VGF-Luc / K2Lmut / O1L-lacZ were added every other day for 3 times at 5.0×10 7 PFU was directly administered into the tumor on one side (days 0, 2, and 4). In addition, InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin clone LTF-2 (isotype control), and InVivoPlus anti-mouse CD8α Clone2.43 (BioXCell) were intraperitoneally administered at 200 μg / mouse on days -4, -2, 1, 3, 5, and 7. The results of the treatment effect were verified by measuring tumor volume and recorded in Fig.11 middle. Fig.11 A represents the result when isotype control was given, Fig.11 B shows the results of administering anti-CD8 antibodies. Fig. 9 Similarly, the tumor volumes of both the virus-administered side and the non-administered side were suppressed in VGF-Luc / O1L-lacZ-administered mice and VGF-Luc / K2Lmut / O1L-lacZ-administered mice compared with PBS mice, and there was a significant difference by two-way ANOVA (*P<0.05, ***P<0.001). On the other hand, when anti-CD8 antibodies were administered, a slight decrease was found in the virus-administered group on the virus-administered side compared with PBS, and no difference was found in all groups on the non-administered side. Therefore, it is shown that the infiltration of CD8 T cells is important not only on the virus-non-administered side but also on the administered side.

[0134] Example 7 Therapeutic effect of vaccinia virus with cell fusion ability in progressive tumor-bearing model mice

[0135] The homologous transplant model was used to investigate the proliferation and spread of the virus in the mouse body and the therapeutic effect of the virus when the tumor volume in the mouse body further increased.

[0136] Mouse colon cancer cell line (CT26) was cultured at 5.0×10 5 The cells were transplanted subcutaneously into the abdomen of BALB / cAjcl mice and the tumors were allowed to grow to 87-253 mm in about 10 days. 3( Average 150mm 3 )( Fig.12 A). After tumor growth, VGF-Luc / O1L-lacZ and VGF-Luc / K2Lmut / O1L-lacZ were added 3 times every other day at 5.0×10 7 PFU was directly administered into the tumor (days 0, 2, and 4). In addition, the viral FLuc luminescence (≒viral proliferation and spread) was non-invasively detected by administration of Vivo Glo Luciferin (Promega) and using an in vivo imaging system (Berthold, NightSHADE LB985) (days 1, 3, 5, and 7) ( Fig.12 B). Figure 13-1 The results of the viral FLuc expression test on the first day after the virus was administered are shown in FIG. When the results of the viral FLuc expression test are seen, it is found that the expression signal of VGF-Luc / K2Lmut / O1L-lacZ is higher than that of VGF-Luc / O1L-lacZ on the first day after the virus was administered ( Figure 13-1 ). When further quantitative analysis of FLuc was performed, it was found that there was a significant difference in the two-way ANOVA statistical analysis one day after the administration of the virus ( Figure 13-2 )(***P<0.001). Thus, it was confirmed that VGF-Luc / K2Lmut / O1L-lacZ actively multiplies and spreads the virus in vivo. Then, the anticancer effect of the virus was studied by measuring the tumor diameter. The results showed that the tumor volume of VGF-Luc / K2Lmut / O1L-lacZ virus-administered mice was significantly inhibited on the 19th day after virus administration, compared with mice not given virus (PBS) and mice given VGF-Luc / O1L-lacZ virus. This was confirmed by two-way analysis of variance (*<0.05, ***<0.001)( Fig.14 ).

[0137] Example 8 Anticancer Effect of Vaccinia Virus Having Both Cell Fusion and Tumor Targeting Capabilities

[0138] Regarding the improvement of anticancer effects by cell fusion, in order to confirm that the above-mentioned K2L mutation can be applied not only by cell fusion but also by all mutations and deletions or foreign gene insertions, and that it can be combined with all methods not only by utilizing the tumor specificity of the above-mentioned VGF and O1 deletions, the following various vaccinia viruses having both cell fusion ability and tumor targeting ability were prepared, and the anticancer effects in vitro were comparatively evaluated.

[0139] As vaccinia viruses having both cell fusion ability and tumor targeting ability, the following clones were used.

[0140] VGF-LucGFP / ΔK2L-BFP / O1L-DsRed( Figure 15-1 A)

[0141] K2L-deficient cells with cell fusion ability, VGF-deficient cells and O1L-deficient cells with tumor-specific clones

[0142] VGF-LucGFP( Figure 15-1 B)

[0143] Tumor-specific cloning ensured by VGF deficiency

[0144] TK-GFP( Figure 15-1 C)

[0145] Tumor-specific cloning ensured by TK deficiency

[0146] Unmodified virus ( Figure 15-1 D)

[0147] Clones that are not deficient in K2L, VGF, O1L, and TK

[0148] VGF-LucGFP / K2L-BFP( Figure 15-1 E)

[0149] K2L-deficient cells have the ability to fuse, and tumor-specific cloning is ensured by VGF deficiency

[0150] K2L-BFP / TK-GFP( Figure 15-1 F)

[0151] K2L-deficient cells have the ability to fuse, and TK-deficient cells ensure tumor-specific clones

[0152] K2L-BFP( Figure 15-1 G)

[0153] K2L-deficient clones with cell fusion ability

[0154] The method for making these clones is shown below.

[0155] In order to prepare a genetically recombinant vaccinia virus completely lacking the K2L gene, a plasmid pTNshuttle / ΔK2L-BFP having a sequence (SEQ ID NO: 15) in which the K2L gene is replaced with the BFP gene in the K2L gene and its 5' and 3' flanking regions (SEQ ID NO: 14) was prepared. Based on the vaccinia virus (VGF-LucGFP / O1L-DsRed) and the transfer vector plasmid DNA (pTNshuttle / ΔK2L-BFP), and using the expression of BFP as an indicator, the recombinant virus was collected in the same manner as above for PCR screening. For K2L, PCR was performed using the same primers as above (SEQ ID NO: 12 and SEQ ID NO: 13), and for clones in which a PCR product of a predetermined size was detected, the nucleotide sequence of the PCR product was confirmed by direct sequencing to prepare VGF-LucGFP / ΔK2L-BFP / O1L-DsRed ( Figure 15-1 A). In order to insert into the expression unit of a foreign gene different from the K2L gene, the K2L gene region was amplified using genomic DNA of the LC16mO strain as a template using two primers (SEQ ID NO: 16 and SEQ ID NO: 17). The PCR product was digested with restriction endonucleases XbaI and MfeI and cloned into the restriction endonuclease sites XbaI and EcoRI of the pUC19 vector to construct pUC19-K2L. Next, pTNshuttle / TK-SP-BFP was digested with restriction endonucleases SphI and EcoRI, and after blunt-end treatment, the SP-BFP fragment was cloned into the site of the pUC19-K2L vector digested with restriction endonuclease ClaI and blunt-end treated to construct pTNshuttle / K2L-SP-BFP. Based on vaccinia virus (LC16m0 strain, an unmodified virus without genetic recombination) and transfer vector plasmid DNA (pTNshuttle / K2L-SP-BFP), and using the expression of BFP as an indicator, the recombinant virus was collected in the same manner as above for PCR screening. For K2L, PCR was performed using the same primers as above (SEQ ID NO: 12 and SEQ ID NO: 13), and for clones in which a PCR product of a predetermined size was detected, the nucleotide sequence of the PCR product was confirmed by direct sequencing, and K2L-BFP ( Figure 15-1G). In order to insert into the expression unit of a foreign gene different from the TK gene, pEGFP-N1 (KRONTEC Co., Ltd.) was digested with restriction endonucleases AgeI and NotI, and cloned into the same restriction endonuclease site of the pTNshuttle / TK-SP-BFP vector in a manner replacing the BFP gene, thereby constructing pTNshuttle / TK-SP-GFP. Based on vaccinia virus (LC16m0 strain, an unmodified virus without genetic recombination) and transfer vector plasmid DNA (pTNshuttle / TK-SP-GFP), and using GFP expression as an indicator, the recombinant virus was collected in the same manner as above for PCR screening. For TK, PCR was performed using two primers (SEQ ID NO: 18 and SEQ ID NO: 19), and for clones in which a PCR product of a predetermined size was detected, the nucleotide sequence of the PCR product was confirmed by direct sequencing, and TK-GFP ( Figure 15-1 C). In order to prepare a vaccinia virus having both cell fusion ability and tumor targeting ability, based on the VGF-ineffective genetic recombinant vaccinia virus VGF-LucGFP (International Publication No. WO2015 / 076422) or the TK-ineffective genetic recombinant vaccinia virus TK-GFP and the transfer vector plasmid DNA (pTNshuttle / K2L-SP-BFP), the recombinant virus was collected according to the same method as above using the expression of BFP as an indicator for PCR screening. For VGF, PCR was performed using the same primers as above (SEQ ID NO: 10 and SEQ ID NO: 11), for K2L, PCR was performed using the same primers as above (SEQ ID NO: 12 and SEQ ID NO: 13), and for TK, PCR was performed using the same primers as above (SEQ ID NO: 18 and SEQ ID NO: 19). For clones in which a PCR product of a predetermined size was detected, the nucleotide sequence of the PCR product was confirmed by direct sequencing, and VGF-LucGFP / K2L-BFP ( Figure 15-1 E) or K2L-BFP / TK-GFP ( Figure 15-1 F) Each recombinant virus was cultured in A549 cells in large quantities, and then the virus titer was determined using RK13 cells for experimental use.

[0156] Next, cell viability and ICD were studied in vitro. Figure 15-2 and 15-3 In the figure, 10 viruses (VGF-LucGFP / O1L-DsRed ( Figure 1A), VGF-LucGFP / K2Lmut / O1L-DsRed (Figure 1B), VGF-LucGFP / ΔK2L-BFP / O1L-DsRed (Figure 15-1A), VGF-LucGFP / O1L-BFP / HAmut( Figure 1 C), VGF-LucGFP ( Figure 15-1 B), VGF-LucGFP / K2L-BFP ( Figure 15-1 E), TK-GFP ( Figure 15-1 C), K2L-BFP / TK-GFP ( Figure 15-1 F), unmodified virus ( Figure 15-1 D) and K2L-BFP( Figure 15-1 G)) The results of cell survival rate. 4 Human lung cancer cells (A549) were seeded in 96-well plates and cultured at 37°C for 24 hours. Figure 1 and Figure 15-1 The virus with the structure shown in was infected at an MOI of 0.1 (n=3). Then, 72 hours after infection, the cell viability was measured by CellTiter 96 (registered trademark) aqueous non-radioactive cell proliferation assay (Aqueous Non-radioactive Cell Proliferation Assay) (Promega). The result was that compared with the virus without deletion (VGF-LucGFP / O1L-DsRed), the cell viability was significantly reduced in all of the natural mutations of K2L, the complete deficiency of K2L, and the natural mutations of HA (VGF-LucGFP / K2Lmut / O1L-DsRed, VGF-LucGFP / ΔK2L-BFP / O1L-DsRed, VGF-LucGFP / O1L-BFP / HAmut: ***P<0.0001). Thus, it was shown that no matter which method of mutation or deletion is used to inactivate the function of K2L or HA to cause cell fusion, the anti-cancer effect is improved. Furthermore, in all of the recombinant viruses in which VGF does not function (VGF-LucGFP), the recombinant viruses in which TK does not function (TK-GFP), and the viruses without tumor specificity (unmodified viruses), when K2L was inserted or deleted, the cell survival rate was significantly reduced (VGF-LucGFP / K2L-BFP, TK-GFP / K2L-BFP, K2L-BFP: ***P≦0.0001). Therefore, it was shown that if cell fusion occurs, the anticancer effect is improved regardless of the type and presence of tumor specificity. Figure 15-4 and 15-5The results of ICD induction when A549 cells were infected with 10 different viruses as above were shown. 4 / well were inoculated in a 24-well plate and cultured at 37°C for 24 hours. Figure 1 and Figure 15-1 The virus with the structure shown in was infected at MOI=1 (n=3). Then, the cell supernatant was collected 60 hours after infection and quantified using HMGB1 ELISA Kit II (Shino-Test). As a result, it was found that compared with the virus without mutation or deletion (VGF-LucGFP / O1L-DsRed), the natural mutation of K2L, the complete deficiency of K2L, and the natural mutation of HA all had significant extracellular release of HMGB1 (VGF-LucGFP / K2Lmut / O1L-DsRed: ***P<0.0001, VGF-LucGFP / ΔK2L-BFP / O1L-DsRed: *P=0.0102, VGF-LucGFP / O1L-BFP / HAmut: **P=0.0011). This shows that no matter what form of mutation or deletion makes K2L or HA ineffective to cause cell fusion, the ICD induction ability is improved. Furthermore, in all of the recombinant viruses in which VGF does not function (VGF-LucGFP), the recombinant viruses in which TK does not function (TK-GFP), and the viruses without tumor specificity (unmodified viruses), when K2L was inserted or deleted, the extracellular release of HMGB1 was significantly increased (VGF-LucGFP / K2L-BFP: **P=0.0010, TK-GFP / K2L-BFP: ***P=0.0002, K2L-BFP: **P=0.0042). Therefore, it was shown that when cell fusion occurs, the ICD inducing ability is improved regardless of the type and presence of tumor specificity.

[0157] The above results show that the anti-cancer effect is improved by inducing cell fusion through vaccinia virus. When analyzing its mechanism, it was found that it was caused by the following three points. First, the oncolytic ability is improved by improving the proliferation and transmission ability of the virus, and apoptosis and necrosis occur actively. Then, through fusion, ICD is more effectively induced and the infiltration of CD8 T cells to the given and non-given sides is enhanced. Finally, by improving the immune environment in the tumor on the given and non-given sides, cancer immunity becomes easier to work. That is, compared with oncolytic viruses that do not induce cell fusion, oncolytic viruses that induce cell fusion more effectively transform cold tumors where immunity is difficult to work into hot tumors that are susceptible to immune attack, thereby exerting a higher anti-cancer effect ( Fig.16 ).

[0158] Example 9 Therapeutic effect of combined use of vaccinia virus with cell fusion ability and anti-PD-1 antibody

[0159] Since the role of CD8 T cells is shown to be important for the therapeutic effect of the virus, especially the therapeutic effect on the untreated side, the role of CD8 T cells was promoted by combining it with anti-PD-1 antibodies as immune checkpoint inhibitors. Mouse colon cancer cell line (CT26) was inoculated with 5.0×10 5 The cells were transplanted subcutaneously on both sides of the abdomen of BALB / cAjcl mice and the tumors were allowed to grow to 42-135 mm in 5 days. 3( Average 70mm 3 After the tumors grew, VGF-Luc / O1L-lacZ and VGF-Luc / K2Lmut / O1L-lacZ were added every other day for 3 times at 5.0×10 7 PFU was directly administered into the tumor on one side (days 0, 2, and 4). In addition, PBS or InVivoPlus anti-mouse PD-1 Clone RMP1-14 (BioXCell) was intraperitoneally administered at 200 μg / mouse on days 3, 5, 7, 9, and 11. Fig.17 ). At this time, the antibody was administered on the second day after the vaccinia virus was administered. From the second administration of the vaccinia virus, the virus was administered three times in total and the antibody was administered five times in total, alternating between the vaccinia virus and the antibody every day. The results of the therapeutic effect were verified by measuring the tumor volume and are recorded in Fig.18 middle.

[0160] When no antibody was given, Fig. 9 Similarly, tumor volume was suppressed in both VGF-Luc / O1L-lacZ-administered mice and VGF-Luc / K2Lmut / O1L-lacZ-administered mice on the virus-administered side, and two-way ANOVA statistical analysis showed a significant difference compared with PBS-administered mice (***P<0.001). Fig. 9Similarly, by administering VGF-Luc / K2Lmut / O1L-lacZ, although the above tumor suppression effects were obtained when PBS or VGF-Luc / O1L-lacZ was administered, the tumor was not relieved in most mice. On the other hand, when anti-PD-1 antibodies were used in combination, the tumor suppression effect when the virus was administered on the virus-administered side was enhanced, and the administered tumor was relieved in 3 / 5 mice administered with VGF-Luc / O1L-lacZ and in all (6 / 6) mice administered with VGF-Luc / K2Lmut / O1L-lacZ. Furthermore, on the side where the virus was not administered, the combined use of anti-PD-1 antibodies also greatly enhanced the therapeutic effect of the virus, but the tumor on the non-administered side was not relieved in the VGF-Luc / O1L-lacZ-administered mice. On the other hand, compared with VGF-Luc / O1L-lacZ-administered mice, VGF-Luc / K2Lmut / O1L-lacZ-administered mice had significantly suppressed tumor volume, which was confirmed by two-way ANOVA statistical analysis (***<0.001), and tumors on both the administered and non-administered sides were alleviated in 3 / 6 mice. Fig.19 The figure shows the survival curve of mice administered with anti-PD-1 antibodies after virus administration. Log-rank statistical analysis showed that when no antibody was administered, the survival time of mice administered with VGF-Luc / K2Lmut / O1L-lacZ was significantly prolonged compared with mice administered with PBS (*: P=0.0112), but no significant difference was shown compared with mice administered with VGF-Luc / O1L-lacZ. On the other hand, when anti-PD-1 antibodies were used in combination, mice administered with VGF-Luc / K2Lmut / O1L-lacZ were also able to show a significant effect of prolonging the life of mice compared with both mice administered with PBS and mice administered with VGF-Luc / O1L-lacZ (***: P=0.0007, **: P=0.0066).

[0161] Next, in order to confirm whether the mice that were completely cured of the tumor had immune memory against the tumor, tumor cells were re-transplanted into the completely cured mice. VGF-Luc / K2Lmut / O1L-lacZ and anti-PD-1 antibodies were co-administered, and for mice with tumor remission, the mouse colon cancer cell line (CT26) was inoculated at 5.0×10 5 The cells were transplanted subcutaneously again on both sides of the abdomen. In addition, for comparison, naive BALB / cAjcl mice of the same age were also transplanted subcutaneously with the same tumor cells. Fig. 20 Figure 2 shows the changes in tumor diameter over time after tumor re-implantation. Fig. 9The same tumors grew, but no tumor growth was observed in mice that were transplanted after the tumors were completely cured.

[0162] In summary, it is shown that the combined use of anti-PD-1 antibodies can greatly enhance the therapeutic effect of vaccinia virus with cell fusion ability and promote the induction of anti-tumor immunity and the formation of immune memory.

[0163] Industrial Applicability

[0164] Vaccinia viruses that induce cell fusion of infected cells can be used to treat cancer.

[0165] All publications, patents and patent applications cited in this specification are incorporated herein by reference in their entirety.

[0166] Sequence Listing Free Text

[0167] 1~4, 7, 8, 10~13, 16~19: primers. Sequence Listing <110> National University Corporation Tottori University <110> Evolution Biotherapeutics Ltd. <120> Vaccinia virus inducing cell fusion and its application <130> PH-8396-PCT <150> JP 2019-091609 <151> 2019-05-14 <160> twenty one <170> PatentIn version 3.5 <210> 1 <211> 37 <212> DNA <213> Artificial <220> <223> Primers <400> 1 atggccggac cggccaccgg tcgccaccat gagcgag 37 <210> 2 <211> 41 <212> DNA <213> Artificial <220> <223> Primers <400> 2 tcgaattcgc tagcggccgc ttaattaagc ttgtgcccca g 41 <210> 3 <211> 20 <212> DNA <213> Artificial <220> <223> Primers <400> 3 acagggatta agacggaaag 20 <210> 4 <211> 20 <212> DNA <213> Artificial <220> <223> Primers <400> 4 gtcaacaagc atcttccaac 20 <210> 5 <211> 1110 <212> DNA <213> Vaccinia virus <400> 5 atgattgcgt tattgatact atcgttagcg tgttcagcgt ccgcctatcg tctacaagga 60 tttaccaatg ccggtatagt agcgtataaa aatattcaag atgataatat tgtcttctca 120 ccgtttggtt attcgttttc tatgtttatg tcgctattgc ctgcatcagg taatactaga 180 atagaattat tgaagactat ggatttgaga aaaagagatc tgggtccagc atttacagaa 240 ttaatatcag gattagctaa gctgaaaaca tctaaatata cgtacactga tctaacttat 300 caaagttcg tagataatac tgtgtgtatt aaaccgtcgt attatcaaca atatcataga 360 ttcggcctat atagattaaa ctttagacga gatgcggtta ataaaattaa ttctatagta 420 gaacgtagat ccggtatgtc taatgtagta gattctaata tgctcgacaa tatactcta 480 tgggcaatca ttaatactat atattttaaa ggtatatggc aatatccgtt tgatatcact 540 aaaacacgca atgctagttt tactaataag tacggtacga aaacggttcc catgatgaac 600 gtagttacta aattgcaagg aaatacaatc acaatcgatg acaaagaata tgacatggta 660 cgccttccgt ataaggatgc tatattagt atgtacctgg caataggtga tatatgacc 720 catttcacag attctatcac ggctgcaaaa ttagactatt gatcgtttca attagggaat 780 aaagtgtaca atcttaaact ccctaaattt tctatcgaaa ataagaggga tattaagtcg 840 atagccgaaa tgatggctcc tagtatgttt aatccagata atgcgtcgtt taaacatatg 900 actagggacc cattatatat ttataaaatg tttcagaatg caaagataga tgtcgacgaa 960 caaggaactg tagcagaggc atctactatt atggtagcta cggcgagatc atctcctgaa 1020 aaactggaat ttaatacacc atttgtgttc atcatcagac atgatattac tggatttata 1080 ttgtttatgg gtaaggtgga atctccttaa 1110 <210> 6 <211> 932 <212> DNA <213> Vaccinia virus <400> 6 atgacacgat taccaatact tttgttacta atatcattag tatacgctac accttctcct 60 cagacatcta aaaaataggt gatgatgcaa ctctatcatg taatcgaaat aatacaaatg 120 actacgttgt tatgagtgct tggtataagg agcccaattc cattattctt ttagctgcta 180 aaagcgacgt cttgtatttt gataattata ccaaggataa aatatcttac gactctccat 240 acgatgatct agttacaact atcacaatta aatcattgac tgctagagat gccggtactt 300 atgtatgtgc attctttatg acatcgccta caaatgacac tgataaagta gattatgaag 360 aatactccac agagttgatt gtaaatacag atagtgaatc gactatagac ataatactat 420 ctggatctac acattcaccg gaaactagtt ctgagaaacc tgattatata gataattcta 480 attgctcgtc ggtattcgaa atcgcgactc cggaaccaat tactgataat gtagaagatc 540 atacagacac cgtcacatac actagtgata gcattaatac agtaagtgca tcatctggag 600 aatccacaac agacgagact ccggaaccaa ttactgataa agaagaagat catacagtca 660 cagacactgt ctcatacact acagtaagta catcatctgg aattgtcact actaaatcaa 720 ccaccgatga tacgtacaat gataatgata cagtaccacc aactactgta ggcggtagta 780 caacctctat tagcaattat aaaaccaagg actttgtaga aatatttggt attaccgcat 840 taattatatt gtcggccgtg gcaatattct gtattacgta ttatatatgt aataaacgtt 900 cacgtaaata caaaacagag aacaaagtct ag 932 <210> 7 <211> 33 <212> DNA <213> Artificial <220> <223> Primer <400> 7 gctccggacg ccaccatgga agatgccaaa aac 33 <210> 8 <211> 39 <212> DNA <213> Artificial <220> <223> Primer <400> 8 gcgaattcgc tagcttacac ggcgatcttg ccgcccttc 39 <210> 9 <211> 3076 <212> DNA <213> Escherichia coli (E. coli) <400> 9 accggtcgcc accatggacc cggtggtgct gcagaggcgg gattgggaga atcctggggt 60 gacgcagctg aatcggctgg ctgctcaccc accatttgca tcatggagaa attccgaaga 120 ggcccggacc gaccgcccct ctcagcagct cagaagtctt aatggagaat ggcgcttcgc 180 atggtttcct gctcccgagg ctgtaccgga aagttggctc gagtgcgatt tgcccgaggc 240 agataccgtc gtggttccct ccaactggca gatgcacggc tatgatgccc ctatctacac 300 caatgtcact taccctataa cagtgaaccc accctttgtg cctaccgaga atcccaccgg 360 atgctacagt ctgacattta acgtggacga gtcttggctg caggaaggcc agactagaat 420 catcttcgat ggtgtcaaca gcgcttttca tctgtggtgc aacgggcgtt gggtgggtta 480 cggccaagac agtaggctcc cttctgaatt cgatctctct gccttcctgc gggccggtga 540 gaatagactt gccgttatgg ttctgcgttg gagcgacggt tcctacctgg aggaccagga 600 tatgtggagg atgtctggca ttttccgaga tgtgagcctc cttcacaaac ctaccactca 660 aatctccgac tttcatgttg ccacaaggtt caacgacgac ttttcacgcg ctgttctgga 720 ggccgaggtc caaatgtgcg gcgaactgcg cgattatctg cgcgtgactg tgagcctttg 780 gcaaggagag acacaggtgg catcaggcac cgcacccttc ggcggagaaa tcatcgacga 840 acggggagga tatgctgata gggttactct taggctgaat gtagaaaacc ccaagctctg 900 gtctgcagaa atacctaacc tctatcgcgc agttgtggaa ctgcacacgg cagacgggac 960 cctgattgaa gccgaagcct gtgacgtcgg cttccgtgaa gtgcgcatcg agaatgggct 1020 gctccttctt aacggtaagc cactgttgat cagaggcgtg aataggcatg agcatcatcc 1080 gctccacgga caggtgatgg atgagcagac aatggttcag gacatactct tgatgaaaca 1140 gaacaacttc aatgccgtgc gctgtagcca ctaccctaat caccactgt ggtataccct 1200 gtgtgacagg tacggcctgt atgtcgtgga tgaggcaaac attgaaactc atggcatggt 1260 gccaatgaat cggctgacag atgaccccag atggctgccc gccatgtcag agcgtgtgac 1320 caggatggta cagcgggaca gaaatcaccc cagtgtcata atctggtccc ttgggaacga 1380 atcagggcat ggtgcaaacc acgatgctct gtaccgctgg attaagagcg ttgaccctag 1440 tcggccagtg cagtatgaag gtggaggcgc cgataccact gcaactgaca ttatttgccc 1500 aatgtacgct cgggtcgacg aggatcaacc gttccctgcg gtcccaaagt ggagcattaa 1560 gaaatggctg tctttgcctg gagaaacacg cccgctgatt ctgtgcgaat atgcccacgc 1620 aatggggaac tccctgggcg ggtttgcaaa gtattggcag gcttttcgcc agtatccacg 1680 actgcaggga ggctttgtgt gggactgggt agatcagagc ctgatcaaat acgacgaaaa 1740 tggcaatcca tggtccgcct atggaggtga ctttggtgat acccctaatg acaggcagtt 1800 ttgcatgaac ggactcgtct ttgcagatcg aactccacat ccggccctga ctgaggccaa 1860 gcatcagcag caattcttcc agtttcggct gtctgggcag accattgagg tgacttccga 1920 gtacttgttt cgacacagcg acaatgagct gctgcactgg atggtggccc tcgatggcaa 1980 accactggcc tcaggagagg tgcccctgga tgtagcgccc caggggaaac agcttatcga 2040 gttgcccgaa ctgccccaac ccgagtctgc tgggcaactc tggcttaccg tgcgagtcgt 2100 tcagccaaat gccactgcct ggtccgaggc tggccacatt agcgcatggc agcagtggag 2160 actggctgag aacctcagcg ttacccttcc cgcagcctct cacgccatcc ctcacttgac 2220 cactagtgag atggacttct gtatcgagct gggcaacaaa cgctggcagt ttaacagaca 2280 gtcaggcttc ttgtcccaga tgtggattgg cgacaagaag cagctgttga cccctttgcg 2340 ggatcagttc acaagggcgc ctctggacaa tgacatcgga gtgagcgagg ctacacgaat 2400 agatccaaac gcgtgggtcg agaggtggaa ggcggctggg cactaccaag ctgaagcggc 2460 cctgttgcaa tgtaccgccg atacgctcgc cgatgccgtc ctcattacga cagcccacgc 2520 ttggcagcac cagggcaaaa cactgtttat ctcccgtaag acatacagaa tcgatggcag 2580 cggtcaaatg gccattacgg tagacgtgga agttgcgtca gatacacccc atcccgcgag 2640 gatcggactg aactgtcaat tggcccaagt cgcagagaga gtgaactggc tgggactcgg 2700 gcctcaggag aattatccag accggctcac agccgcttgc ttcgataggt gggaccttcc 2760 actctctgat atgtacaccc catacgtgtt cccctcagag aatggcctgc ggtgtgggac 2820 acgagaactg aactacggac cgcatcagtg gagaggggac ttccagttca acatcagccg 2880 gtatagtcag cagcagctga tggaaacgtc ccatagacat ctgctgcacg ctgaggaagg 2940 gacatggctg aacattgacg ggttccacat gggaataggt ggcgatgaca gctggtcccc 3000 tagcgtaagc gccgagtttc aactgagtgc tgggagatat cattaccaac tggtctggtg 3060 ccagaaatga gctagc 3076 <210> 10 <211> 20 <212> DNA <213> Artificial <220> <223> Primer <400> 10 ggtaacgcta tcgaaacgac 20 <210> 11 <211> 20 <212> DNA <213> Artificial <220> <223> Primer <400> 11 ttagttcgtc gagtgaacct 20 <210> 12 <211> 20 <212> DNA <213> Artificial <220> <223> Primer <400> 12 caaggcacta tgaccgttga 20 <210> 13 <211> 20 <212> DNA <213> Artificial <220> <223> Primer <400> 13 gcgatgagat acaaccggaa 20 <210> 14 <211> 2110 <212> DNA <213> Vaccinia virus <400> 14 cttgtcatca aattgtgaat catccagtcc actgaatagc aaaatcttta ctattttagt 60 atcttccaat gtggctgcct gatgtaatgg aaattcattc tctagaagat ttttcaatgc 120 tccagcgttc aacaacgtac atactagacg cacgttatta tcagctattg cataatacaa 180 ggcactatga ccgttgatat ccgccttaaa tgcatctttg ctagagagaa agcttttcag 240 ctgcttagac ttccaagtat taattcgtga cagatccatg tctgaaacaa gacgctaatt 300 agtgtatatt ttttcatttt ttataatttt gtcatattgc accagaatta ataatatctc 360 taatagatct gattagtaga tacatggcta tcgcaaaaca acatatacac atttaataaa 420 aataatattt attaagaaaa ttcagatttc acgtacccat caatataaat aaaataatga 480 ttccttacac cgtacccata ttaaggagat tccaccttac ccataaacaa tataaatcca 540 gtaatatcat gtctgatgat gaacacaaat ggtgtattaa attccagttt ttcaggagat 600 gatctcgccg tagctaccat atatagtagat gcctctgcta cagttccttg ttcgtcgaca 660 tctatctttg cattctgaaa cattttataa atatataatg ggtccctagt catatgttta 720 aacgacgcat tatctggatt aaacatacta ggagccatca ttcggctat cgacttaata 780 tcccttat ttcgataga aaatttaggg agtttaagat tgtacacttt attccctaat 840 tgaaacgacc aatagtctaa ttttgcagcc gtgatagaat ctgtgaaatg ggtcatatta 900 tcacctattg ccaggtacat actaatatta gcatccttat acggaaggcg taccatgtca 960 tattctttgt catcgattgt gattgtattt ccttgcaatt tagtaactac gttcatcatg 1020 ggaaccgttt tcgtaccgta cttattagta aaactagcat tgcgtgtttt agtgatatca 1080 aacggatatt gccatatacc tttaaaatat atagtattaa tgattgccca tagagtatta 1140 ttgtcgagca tattagaatc tactacatta gacataccgg atctacgttc tactatagaa 1200 ttattttat taaccgcatc tcgtctaaag ttatctat ataggccgaa tctatgatat 1260 tgttgataat acgacggttt atacacaca gtattatcta cgaaactttg ataagttaga 1320 tcagtgtacg tatattaga tgttttcagc ctgatattaa ttctgtaaat 1380 gctggaccca gatctcttt tctcaatcc atagtctca atattctat tctagtatta 1440 cctgatgcag gcaatagcga cataacata gaaacgaat aaccaacgg tgagagaca 1500 atattatcat cttgaatatt ttatacgct actataccgg cattggtaaa tccttgtaga 1560 cgataggcgg acgctgaaca cgctaacgat agtatcaata acgcaatcat gattttatgg 1620 tattaataat taaccttatt tttagttcg gtataaaaaa attattgatg tctacacatc 1680 cttttgtaat tgacatctat atatcctttt gtataatca ctctaatcac tttaactttt 1740 acagttttcc ctaccagtttt atccctatat tcacatatc tatccatatg catcttaca 1800 ctctctgcca agatagcttc agagtgagga tagtcaaaa gataataata agatagcata 1860 tcattctcgt atactctgcc ctttaca tcaccgcat tgggcaacga atacaaat 1920 gcaagcatct tgttaacggg ctcgtaaatt gggataaaaa ttatgttttt attgtcttat 1980 atctatttta ttcaagagaa tattcaggaa tttctttttc cggttgtatc tcatcgcagt 2040 atatatcatt tgtacattgt tttatatttt ttaatagttt acacctttta gtaggactag 2100 tatcgtacaa 2110 <210> 15 <211> 1702 <212> DNA <213> Artificial <220> <223> Synthetic <400> 15 cttgtcatca aattgtgaat catccagtcc actgaatagc aaaatcttta ctattttagt 60 atcttccaat gtggctgcct gatgtaatgg aaattcattc tctagaagat ttttcaatgc 120 tccagcgttc aacaacgtac atactagacg cacgttatta tcagctattg cataatacaa 180 ggcactatga ccgttgatat ccgccttaaa tgcatctttg ctagagagaa agcttttcag 240 ctgcttagac ttccaagtat taattcgtga cagatccatg tctgaaacaa gacgctaatt 300 agtgtatatt ttttcatttt ttataatttt gtcatattgc accagaatta ataatatctc 360 taatagatct gattagtaga tacatggcta tcgcaaaaca acatatacac atttaataaa 420 aataatattt attaagaaaa ttcagatttc acgtacccat caatataaat aaaataatga 480 ttccttacac cgtacccata ttaattaagc ttgtgcccca gtttgctagg gaggtcgcag 540 tatctggcca ctgccacctc gtgctgctcg acgtaggtct cgttgttggc ctccttgatt 600 ctttccagtc tgtagtccac atagtagacg ccaggcatct tgaggttctt agcgggtttc 660 ttggatctat atgtggtctt gatgtttgcg atcagatggc tcccgcccac gagcttcagg 720 gccatgtcgt ttctgccttc caggccgccg tcagcggggt acagcgtctc ggtgaaggcc 780 tcccagccga gtgttttctt ctgcatcaca gggccgttgg atgtgaagtt cacccctctg 840 atcttgacgt tgtagatgag gcagccgtcc tggaggctgg tgtcctgggt agcggtcagc 900 acgcccccgt cttcgtatgt ggtgactctc tcccatgtga agccctcagg gaaggactgc 960 ttgaagaagt cggggatgcc ctgggtgtgg ttgatgaagg tcttgctgcc gtagaggaag 1020 ctagtagcca ggatgtcgaa ggcgaagggg agagggccgc cctcgaccac cttgattctc 1080 atggtctggg tgccctcgta gggcttgcct tcgccctcgg atgtgcactt gaagtgatgg 1140 ttgtccacgg tgccctccat gtacagcttc atgtgcatgt tctccttaat cagctcgctc 1200 atgattttat ggtattaata attaacctta tttttatgtt cggtataaaa aaattattga 1260 tgtctacaca tccttttgta attgacatct atatatcctt ttgtataatc aactctaatc 1320 actttaactt ttacagtttt ccctaccagt ttatccctat attcaacata tctatccata 1380 tgcatcttaa cactctctgc caagatagct tcagagtgag gatagtcaaa aagataaata 1440 tatagagcat aatcattctc gtatactctg ccctttatta catcacccgc attgggcaac 1500 gaataacaaa atgcaagcat cttgttaacg ggctcgtaaa ttgggataaa aattatgttt 1560 ttattgtctt atatctattt tattcaagag aatattcagg aatttctttt tccggttgta 1620 tctcatcgca gtatatatca tttgtacatt gttttatatt ttttaatagt ttacaccttt 1680 tagtaggact agtatcgtac aa 1702 <210> 16 <211> 20 <212> DNA <213> Artificial <220> <223> Primer <400> 16 ttaacatccg ttgatggaag 20 <210> 17 <211> 20 <212> DNA <213> Artificial <220> <223> Primers <400> 17 ttagtcgcca tgactatctc 20 <210> 18 <211> twenty four <212> DNA <213> Artificial <220> <223> Primers <400> 18 atttctccgt gataggtatc gatg 24 <210> 19 <211> twenty two <212> DNA <213> Artificial <220> <223> Primers <400> 19 aacggtttac gttgaaatgt cc 22 <210> 20 <211> 1110 <212> DNA <213> Vaccinia virus <400> 20 atgattgcgt tattgatact atcgttagcg tgttcagcgt ccgcctatcg tctacaagga 60 tttaccaatg ccggtatagt agcgtataaa aatattcaag atgataatat tgtcttctca 120 ccgtttggtt attcgttttc tatgtttatg tcgctattgc ctgcatcagg taatactaga 180 atagaattat tgagactat ggatttgaga aaagagatc tggtccagc atttacagaa 240 ttatatcag gattagctaa gctgaaaaca tctaatata cgtacactga tctaacttat 300 caaagtttcg tagatatac tgtgtgtatt aaccgtcgt attatcaaca atacataga 360 ttcggcctat atagattaaa ctttagacga gatgcggtta aaaattaa ttctatagta 420 gaacgtagat ccggtatgtc taatgtagta gattctata tgctcgaca taatactcta 480 tgggcaatca ttaatactat atattttaaa ggtatatggc atatccgtt tgatatcact 540 aaaacacgca atgctagttt tactaatag tacggtacga aaacggttcc catgatgac 600 gtagttacta aattgcaagg aaatacaatc acaatcgatg aaagaata tgacatggta 660 cgccttccgt aataggatgc taatattagt atgtacctgg caataggtga taatatgacc 720 cattcacag attctatcac ggctgcaaaa ttagactatt ggtcgttttca attaggaat 780 aaagtgtaca atctttaact ccctaaattt tctatcgaaa atagaggga tattaagtcg 840 atagccgaaa tgatggctcc tagtatgttt aatccagata atgcgtcgtt taaacatatg 900 actagggacc cattatatat tttaaaatg tttcagaatg caaagataga tgtcgacgaa 960 caggaactg tagcagaggc atctattt atggtagcta cggcgagatc atctcctgaa 1020 aaactggaat ttatacacc atttgtgttc atcatcagac atgatattac tggatttata 1080 ttgtttatgg gtaggtgga atctccttaa 1110 <210> 21 <211> 933 <212> DNA <213> Vaccinia virus <400> 21 atgacacgat taccatact ttgttacta atcattag tatacgctac accttctcct 60 cagacatcta aaaaaatagg tgatgatgca acttacat gtaatcgaa taatacaaat 120 gactacgttg ttatgagtgc ttggtataag gagcccatt ccattattct tttagctgct 180 aaaagcgacg tcttgtattt tgatatat accaaggata aaatatctta cgactctcca 240 tacgatgatc tagttacac tatcacatt aaatcattga ctgctagaga tgccggtact 300 tatgtatgtg cattctttat gatacgcct acaatgaca ctgataagt agattgaa 360 gatactcca cagagttgat tgtaataca gatagtgaat cgactataga cataatacta 420 tctggatcta cacattcacc ggaactagt tctgagaac ctgattatat agatattct 480 aattgctcgt cggtattcga aatcgcgact ccggaaccaa ttactgataa tgtagagat 540 catacagaca ccgtcacata cactagtgat agcattaata cagtaagtgc atcatctgga 600 gatccacaa cagacgagac tccggaacca attactgata aagagaga tcatacagtc 660 acagacactg tctcatacac tacagtagt acatcatctg gattgtcac tactaatca 720 accaccgatg atacgtacaa tgataatgat acagtaccac caactactgt aggcggtagt 780 acaacctcta ttagcaatta taaaaccaag gactttgtag aaatattgg tattaccgca 840 ttaattatat tgtcggccgt ggcaatattc tgtattacgt attatatg tataaacgt 900 tcacgtaaat aaaacaga gawaagtc tag 933

Claims

1. A mutant vaccinia virus capable of causing cell fusion of infected cells, wherein: The K2L gene or HA gene of the mutated vaccinia virus is defective in function, and the vaccinia virus growth factor (VGF) gene and O1L gene of the mutated vaccinia virus are defective in function, wherein the vaccinia virus is LC16 strain, LC16mO strain or LC16m8 strain modified to express the B5R gene, and the defective gene function means that the gene cannot express normal gene products due to deletion and mutation.

2. The vaccinia virus according to claim 1, which is an oncolytic vaccinia virus.

3. The vaccinia virus according to claim 2, which does not proliferate in normal cells but specifically proliferates in cancer cells and has oncolytic properties that specifically destroy cancer cells.

4. A pharmaceutical composition for treating cancer, comprising the vaccinia virus according to any one of claims 1 to 3. The pharmaceutical composition according to claim 4 , which can enhance systemic anti-cancer immune activity.

6. A vaccinia virus vector, comprising the vaccinia virus according to any one of claims 1 to 3 into which foreign DNA is introduced.

7. The vaccinia virus vector according to claim 6, wherein The foreign DNA is a marker DNA, a therapeutic gene having a cytotoxic or immune-activating effect, or a DNA encoding an antigen of a cancer, virus, bacterium or protozoa.

8. A pharmaceutical composition for treating cancer or as a vaccine against cancer, virus, bacteria or protozoa, the pharmaceutical composition comprising the vaccinia virus vector according to claim 6 or 7.

9. A method for preparing a vaccinia virus, wherein the vaccinia virus causes cell fusion of infected cells and induces cell death, the method comprising making the K2L gene or HA gene of the vaccinia virus defective, and further making the vaccinia virus growth factor (VGF) gene and O1L gene of the vaccinia virus defective, wherein: The vaccinia virus is LC16 strain, LC16mO strain or LC16m8 strain modified to express the B5R gene, and the functional defect of the gene means that the gene cannot express a normal gene product due to deletion and mutation.

10. The preparation method according to claim 9, wherein the vaccinia virus is an oncolytic vaccinia virus.

11. A combination drug kit for treating cancer, wherein: The combination drug set contains the vaccinia virus according to any one of claims 1 to 3 in combination with an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.

12. The vaccinia virus according to any one of claims 1 to 3, for use in treating cancer together with an immune checkpoint inhibitor, wherein Immune checkpoint inhibitors are either anti-PD-1 antibodies or anti-PD-L1 antibodies.